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Abstract 
Micromotors are recognized as promising candidates for untethered micromanipulation and 
targeted cargo transport. Their future application is, however, hindered by the low efficiency 
of drug encapsulation and their poor adaptability in physiological conditions. To address 
these challenges, one potential solution is to incorporate micromotors with biological 
materials as the combination of functional biological entities and smart artificial parts 
represents a manipulable and biologically friendly approach.  
This dissertation focuses on the development of custom-designed micromotors combined 
with sperm and their potential applications on targeted diseases treatment. By means of 2D 
and 3D lithography methods, microstructures with complex configurations can be fabricated 
for specific demands. Bovine and human sperm are both for the first time explored as drug 
carriers thanks to their high encapsulation efficiency of hydrophilic drugs, their powerful 
self-propulsion and their improved drug-uptake relying on the somatic-cell fusion ability. 
The hybrid micromotors containing drug loaded sperm and constructed artificial 
enhancements can be self-propelled by the sperm flagella and remotely guided and released 
to the target at high precision by employing weak external magnetic fields. As a result, 
micromotors based on both bovine and human sperm show significant anticancer effect. The 
application here can be further broadened to other biological environments, in particular to 
the blood stream, showing the potential on the treatment of blood diseases like blood 
clotting. Finally, to enhance the treatment efficiency, in particular to control sperm number 
  
 
and drug dose, three strategies are demonstrated to transport swarms of sperm. This 
research paves the way for the precision medicine based on engineered sperm-based 
micromotors. 
Keywords: micromotors, sperm, drug delivery, cancer treatment, blood diseases, 
untethered robotics 
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1. General introduction 
 Motivation and goals 
Since the microworld started to show itself to human beings, people have been dreaming to 
make a nano or microscale vehicle that can voyage in the microworld, transport cargos and 
perform more complex operations based on one’s imagination. In 1951, Taylor first 
discussed the swimming behavior of microorganisms and proposed a sheet model for the 
movement of the cells with flagella.1 In 1959, Feynman passionately contemplated the future 
use of microscale robots in his historic lecture “There is plenty of room at the bottom”. He 
specifically suggested the idea to “swallow a surgeon” to treat the wounds deep in our body 
where the traditional tools cannot reach and do the job in a non-invasive way.2 This has 
fascinated people in the miniaturization of robots ever since. A famous movie “Fantastic 
Voyage” in 1966 picked up this idea and brought the audience into a future world where 
scientists could miniaturize a sailor in a microscale submarine so that they can travel in the 
blood circulation system and cure an injury in the human body, in particular performing 
laser ablation to tumor.3  
Certainly, researchers have also been inspired and dedicated a huge effort on the study of 
robotics at the microscale. Diverse creative microscale robots (termed micromotors, 
microjets, microengines, microswimmers, or micropropellers, of which the sizes usually 
between 100 nm to 1 mm) have been invented and leading us closer and closer to valuable 
biomedical applications.4 Medical treatments based on micromotors benefit from their 
mobility, compared to the earlier developed passive drug carriers, such as liposomes, 
nanoparticles and microcapsules.5 During the use of passive drug delivery systems in the 
past decades, more and more problems have emerged, such as undesired accumulation due 
to the lack of active actuation system, fast clearance and degradation due to the elimination 
of the liver and blood,6 decreased effective drug concentration due to the dilution by body 
fluid7 and limited tissue penetration.8 To address such challenges, micromotors are 
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therefore expected to be one of the next generation of drug delivery solution. To do the job 
at the microscale, micromotors have to overcome several hurdles. Firstly, locomotion of 
micromotors at low Reynold numbers in liquid environments are facing more difficulties 
than the macroscopic motors, due to the relatively strong Brownian noise under a negligible 
impact of the inertia.4 Second, as the problem-solving abilities of micromotors rely on 
specific functionalizations or loaded cargos, elegant techniques are needed to endow 
micromotors with specific abilities without damaging them, which represents big challenges 
on manipulation at the microscale. Moreover, regarding the biomedical applications, the 
adaptability of micromotors can never be ignored. This also excludes all micromotors relying 
on extreme conditions which are harmful to the human body, such as high voltage electric 
field, violent chemical reactions and pathogenic bacteria. To address these challenges, 
combining biological components is expected as an efficient solution. 
 
Figure 1. Prospective scenario of micromotors working in blood.9 Reproduced with 
permission from © Conference Series LLC Ltd. 
 
The sperm, as a highly differentiated cell, is a promising candidate to construct a hybrid 
micromotor to address the abovementioned challenges, thanks to the powerful propulsion 
provided by the sperm and its openness to various functionalizations for diverse 
applications. With the help of precise nano-manufacturing method, nowadays it is not as 
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unimaginable as before to artificially equip sperm to be functional micromotors as 
demanded. All of these motivate us to the main goal to develop novel sperm hybrid 
micromotors (sperm-motors) that could potentially work in the human body. These sperm-
motors could be precisely navigated to the target site and controllably treat the diseases in 
situ in a non-invasive way. 
 Structure of the dissertation 
This dissertation is organized as follows: 
Chapter 2 introduces the background of the micromotors, from the manufacturing means at 
the microscale to the current research advances, focusing on biomedical applications. 
Thereafter, the superiority of the sperm as a biohybrid component to construct micromotors 
is emphasized, highlighting the motivation to develop sperm-motors towards disease 
treatment. 
Chapter 3 details the experimental procedures in the manufacturing of the artificial 
component of sperm-motors, the functional treatment of sperm, the construction of sperm-
motors and the essential evaluations of their applications on disease treatment. 
Chapter 4 demonstrates the development of a tetrapod-like sperm-motor (sperm-tetrapod) 
and its application on cancer treatment. The artificial component here has a tubular body 
that can couple the sperm, and four arms that can bend and controllably release the sperm. 
The sperm-tetrapod can be precisely guided by an external magnetic field relying on the 
magnetic coating on the artificial component. When the sperm is loaded with anti-cancer 
drug, the sperm-tetrapod shows an effective cancer cell-killing effect. 
Chapter 5 shows our exploration of the anti-cancer usage of sperm from bovine sperm 
treating over-passaged cancer cells to human sperm treating early passaged cancer lesion. 
Research in this chapter explains the suitability of sperm as drug carriers and introduces this 
sperm-based system one step closer to the application in the human body. 
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Chapter 6 demonstrates the development of a sperm-motor based on a streamline-horned 
cap (SHC) and its application in the blood circulation system. Achievements presented in this 
chapter not only broadens the administration route of the sperm-motor based drug delivery 
system, but also opens the gate for micromotors’ application in blood against flow 
comparable to the realistic blood stream in the human body.  
Chapter 7 introduces several strategies for multiple sperm transport towards higher drug 
dose based on more sperm and artificial components, or towards higher working efficiency 
of sperm. Particularly, a transport system based on a sperm adherent microflake and a 
helical microcourier is highlighted. 
Chapter 8 summarizes all the achievements during the research and concludes the 
dissertation. Outlook with the following research directions and future applications is 
discussed. 
  
 5 
 
2. Background and state-of-the-art 
 Manufacturing at the microscale 
In the development of microrobotics, there has been a high demand for smaller and smaller 
machinery parts with more and more fine structures. Traditional macro mechanical 
manufacturing technology cannot meet the requirements of the machining precision of these 
microscale systems. Fine processing with a resolution at the nanoscale is thus critically 
important. 
Bottom-up methods based on phase transition mechanism have been widely used to prepare 
passive micro or nanoscale drug delivery systems, such as liposomes, nanoparticles, 
microspheres and microcapsules.10 However, no fine structure can be obtained from this 
uncontrollable technique based on self-assembling.11 On the contrary, micro- and 
nanomanufacturing technology based on photo-lithography makes it possible to precisely 
design and polish the required devices or parts in details. This top-down technology allows 
specific reactions, for example photopolymerization, occurring locally at the specified 
position based on pre-programmed design. The patterning at the microscale mainly relies 
on a pre-fabricated mask or a maskless method based on directly laser writing.12 However, 
the diffraction limit of lasers restricts the manufacturing resolution,13 which has motivated 
the development of varieties of lithography methods in the recent decades (e.g. extreme 
ultraviolet lithography (EUVL), electron beam lithography (EBL), nanoimprint lithography 
(NIL), etc.), focusing on decreasing the wavelength of the laser, increasing the exposure 
intensity and dipping the lens in specific immersion liquids.13 Among all existing lithography 
techniques, two-photon lithography has been regarded as one of the most promising 
methods to fabricate three-dimensional (3D) structures,14 especially for the fabrication of 
micromotors. 
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2.1.1. Femtosecond two-photon lithography (FSTL) 
Traditional lithography is generally a single-photon exposure process in 2D. Although 2D 
exposure technique can be used to manufacture the device with shape change in the third 
dimension by exposing the resist layer by layer, it is not possible to construct complex 3D 
structure with high resolution. The solution is to combine two techniques, two-photon 
lithography and femtosecond pulsed laser. FSTL is an ultra-fine processing technique that 
integrates ultra-fast laser technique, ultrahigh-precision positioning technique and photo-
polymerization technique.15 
 Mechanism of FSTL 
Femtosecond laser is an ultra-fast laser with a time-bandwidth at the femtosecond scale. It 
has ultra-high instantaneous power due to the highly repeated frequencies of the lasers. This 
high power enables the structure change of the material at the molecular level, inducing 
etching or polymerization. Besides, it has ultra-short pulse duration of the order of 10-12 
second.16 This short action time does not induce thermal effect, protecting the treated 
material from thermal deformation.17 Thus, FSTL only allows the chemical change of the 
photoresist occurring at the focal spot of the laser after a two-photon absorption, generating 
programmable 3D patterns. Since FSTL is seldom used on positive-tone resists, we will focus 
on its application on two-photon polymerization in this chapter. Figure 2.1a explains the 
process of two-photon absorption differently from a general single-photon absorption. In 
the process of a single-photon absorption, a molecule at the ground state absorbs one photon 
when the photon energy of the excitation laser equals the energy distance between the 
ground state and the excitation state of the electron. Then the excited electron induced the 
formation of breaking of specific chemical bonds.14 In the two-photon absorption process, 
the illuminated molecule absorbs the first photon and goes into a virtual state with a very 
short duration or an actual state in a generally called stepwise absorption process. Local 
polymerization can result when the second photon arrives before the excited state decays. 
The absorption rate of two-photon process is formulated below:18 
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𝑃 = 𝜎
𝐼2
ℎ𝑣
 
 
where P represents the two-photon absorption rate, σ represents the two-photon 
absorption coefficient, I represents the illumination light intensity, h represents Planck 
constant and v represents the excitation light frequency. Since the two-photon absorption 
rate is directly proportional to the squared excitation light intensity, femtosecond laser stays 
as an advantageous choice for the laser source thanks to its high intensity density within a 
pulse duration. Besides, the two-photon induced polymerization only occurs at the position 
where the illumination intensity exceeds a certain threshold, as shown in Figure 2.1b. When 
the laser with a high intensity but a long wavelength is used, the size of the illumination 
threshold can be adjusted much smaller than the size of the focused laser spot, decided by 
the nonlinear optical effect of the applied material. Thus, the polymerization size of FSTL is 
much smaller than the laser diffraction limit, improving the manufacturing fineness to below 
100 nanometers.18 Besides, FSTL allows the efficient absorption through a thin film or non-
transparent liquid sample by using infrared laser.19 Combined with an ultra-precise 
motorized objective stage, 3D manufacturing with fine details below 100 nm can be achieved 
by precisely controlling the laser on/off and the focusing position out of pre-programmed 
CAD codes. 
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Figure 2.1. Difference between single-photon and two-photon absorption processes on (a) 
energy level; (b) exposure area. 
 
A general FSTL platform is depicted in Figure 2.2. Femtosecond laser is focused inside the 
material through an objective with a large aperture. The exposure time and laser power can 
be adjusted by the shutter and attenuator. The exposure position is controlled by a micro-
motorized system comprised of a piezoelectric-drive micro displacement platform, a 
galvanometers array and a motorized stage of the microscope. The manufacturing process 
can be real-time monitored by an external CCD system.20,21 There are three positioning 
modes in the FSTL, namely stage moving, galvo scanning and piezo scanning modes. The 
stage movement is used to position the desired region of the photoresist under the objective. 
a 
b 
 9 
 
This positioning can be fast but very coarse. The galvo scanning mode is suitable for the 
segment-to-segment manufacturing method, of which the manufacturing resolution is 
decided on the size of each segment.22 Thanks to a low rotational inertia of the galvo, the 
response of the galvo scanning can be as fast as 0.5 ms. The piezo scanning mode has the 
highest resolution due to a high precision of the piezoelectric-driven platform (1 nm). 
However, due to the high inertia of the platform, the piezo scanning mode needs a long 
waiting time (more than 10 ms) after a large displacement. Thus, the piezo scanning mode is 
appropriate for a point-to-point writing method, in which the distance of two points is below 
50 nm. This method is used to process the details of the sample, slowly but with a high 
resolution. By means of a combination of three positioning modes, microstructures can be 
fabricated precisely and fast in a large number of arrays. 
 
Figure 2.2. Typical FSTL setup 
 Applications of FSTL 
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FSTL makes it possible to manufacture complex devices in 3D dimensions with an ultra-high 
precision at fast speed. Early in 1997, Prof. Kawata in Osaka University first successfully 
fabricated a helical tube with a resolution at 120 nm by using FSTL.20 In 2001, Nature 
reported the milestone research from his group, a 3D micro-cattle around 10 µm long and 7 
µm tall (Figure 2.3a).23 It took them 3 h to fabricate a single structure. Since then, FSTL has 
been largely improved on not only the processing efficiency, but also the processing 
resolution. A surging number of materials have been developed for 3D processing by FSTL 
with diverse properties. In terms of biomedical applications, FSTL are attracting attentions 
from researchers in various fields, including tissue engineering, microscopic imaging, and 
the study of microscale apparatus and new drug delivery strategies. Figure 2.3b illustrates 
a microscaffold made of three different photoresists that can selectively be functionalized 
with different proteins, allowing directed cells attachment in 3D.24 Similarly, Marino et al. 
fabricated a porous microtube as scaffold for endothelial-like cells culture. This cell seeded 
microtube showed a potential to mimic the blood brain barrier.25 Choi et al. recently 
fabricated a series of micromotors by FSTL for the purpose of cells transplantation. The 
micromotors could carry human stem cells and transport them in a mouse brain slice, 
indicating a potential remote control on tissue engineering.26 Representing one of the most 
important applications of FSTL, more applications of FSTL on micromotors will be discussed 
in details in Section 2.2.  
 
Figure 2.3. Examples of FSTL products: (a) Microcattle;23 Reproduced with permission from 
Copyright © 2019, Springer Nature. (b) Microscaffold for cell culture.24 Reproduced with 
a b 
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permission from © 2016 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
2.1.2. Other fabrication methods 
As introduced above, the fabrication of micromotors can be generally classified as top-down 
and bottom-up methods. While FSTL represents one of the most recently established top-
down methods, 2D lithography is the most commonly used one as an inexpensive method 
with high fineness and yield. In general, 2D lithographic processing relies on a pre-prepared 
photomask. The laser beam (e.g. UV light, visible light, ion beam) is projected on the 
photoresist-coated substrate through the mask, resulting in a polymerization or etching on 
the programmed region. The processing resolution is influenced by the fineness of the mask, 
the property of the photoresist and especially the diffraction limit of the applied laser. After 
further steps of baking and developing, 2D patterns at the microscale with the nanoscale 
resolution can be obtained.13 Micromotors can be obtained by coating these microstructures 
with functional metal layers and detaching them off. As an example, our institute fabricated 
a catalytic microtube based on a rolled-up method by 2D lithography in 2009. Platinum 
coating on the surface enabled it to catalyze local decomposition of the H2O2 fuel into O2 
bubbles, initiating an autonomous propelling of the microtube.27 
The bottom-up approach relying on molecular self-assembly is also widely used in the 
fabrication of micromotors without complex structures. The processing is inexpensive and 
fast, though custom design is not supported. Based on different molds or templates, various 
structures including Janus particles, microrods and microtubes can be obtained by 
homogenous phase transition,28 electrodeposition29 and layer-by-layer assembling.30 
Considering the diversity of this approach, more details about the applications will be 
explained in the next section in relation with specific micromotors. As a summary, a chart of 
the fabrication methods for micromotors can be found in Figure 2.4. 
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Figure 2.4. Fabrications methods for micromotors 
 
 Motion at the microscale 
2.2.1. Theory 
Motion of nano and micromotors in a Newtonian fluid is challenged by the absence of inertial 
forces. For an object swimming in fluid, the significance of the inertial forces relative to the 
viscous forces is decided by its Reynolds number, formulated as:4  
𝑅𝑒 =
𝜌𝑎𝑣
𝜂
=
𝐼𝑛𝑒𝑟𝑡𝑖𝑎𝑙 𝑓𝑜𝑟𝑐𝑒𝑠
𝑉𝑖𝑠𝑐𝑜𝑢𝑠 𝑓𝑜𝑟𝑐𝑒𝑠
 
Where ρ is the fluid density, η is the fluid viscosity, v is the moving velocity of the object 
relative to flow and a is the characteristic dimension. Micromotors with low swimming 
velocity have very small Reynolds numbers (Re <<1). For example, for a human sperm 
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swimming in water (a ~ 10 µm, v ~ 100 µm/s, p ~ 103), the Reynolds number is around 10-
3. Propulsion at the microscale at inertia-less regime thus requires fundamentally different 
mechanisms from macroscopic motion. In 1977, Purcell visualized the locomotion factors of 
miniature devices in fluid. To the opposite of macroscopic swimmers, micromotors cannot 
be propelled by time-reversible gliding.31 For instance, when a microscale scallop moves 
forward by flapping its arms, it will return its initial position by resetting its arms, achieving 
zero net displacement (Figure 2.5). In view of this, locomotion at the microscale needs a 
continual propulsion system and an asymmetrical motion mechanism, either by a shape 
change with a deformable body or by a corkscrew-like motion. For example, some bacteria 
propel themselves by continuously bending their flagella. Likewise, sperm swim at a 
combinational mechanism with beating their flexible flagella and screwing their heads.32  
 
Figure 2.5. A microscale scallop in low Reynolds number conditions. 
When the inertial forces are neglected in low Re numbers systems, motion at the microscale 
is highly dominated by the hydrodynamic resistance. In Newtonian fluid, the Navier-stokes 
equations that describe flow property can be then simplified as:33 
−𝛻𝑝 +  𝜇𝛻2𝑢 = 0, 𝛻 ∙ 𝑢 = 0 
 14 
 
Where u represents the flow field, μ represents the fluid viscosity and p represents the flow 
pressure. The linearity and instantaneity of the equations imply that the thrust force of the 
micromotor is counterbalanced by the hydrodynamic resistance (drag force) on it (Fthrust = 
Fdrag).33 This principle has been extensively applied on the calculation of the propulsion force 
of micromotors, as the hydrodynamic resistance of a specific object can be calculated 
according to its configuration, surface features and the fluid properties. With the help of 
finite element analysis, the estimation of the propulsion force has been more and more 
efficient. 
2.2.2. Micromotors for therapeutic applications 
The following section is mainly based on the publication titled on “Micro- and nano-motors: 
the new generation of drug carriers” in Therapeutic Delivery. Reprinted with permission 
from [Therapeutic delivery, 2018, 9(4): 303-316] (doi.org/10.4155/tde-2017-0113).5 
Copyright[2017] Future Science. Micromotors are attractive for diverse biomedical 
applications, especially on targeted drug delivery, offering advantages such as rapid 
transport, high tissue penetration and motion controllability. Compared to passive nano or 
microcarriers (e.g. liposomes, nanoparticels, microspheres) with low targeting efficiency, 
micromotors with powerful propulsion and intelligent guidance mechanisms can precisely 
transport drug to desired locations with a deviation in several micrometers. In general, 
micromotors can be categorized in three types according to the propulsion mode: chemical, 
physical and biological micromotors (Figure 2.6).34 
 
Figure 2.6. Three micromotor prototypes.34 
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 Chemical micromotor 
The chemical micromotor transforms the energy from a local chemical reaction into motion. 
It often contains an active substance (e.g. Mg, Pt, Ag, Pa) which can react with the 
environmental liquid or catalyze the decomposition of it. The micromotor is usually designed 
with asymmetrically distributed active materials to react with the liquid fuel and generate 
bubbles at the back end of the micromotor, facilitating its forward motion. The first 
demonstration of catalytic micromotors to capture and transport cargo was done by Sen’s 
group in 2008, in which an Au-Pt bimetallic nanorod was propelled in H202 solution by the 
decomposition product: O2 bubbles. Polystyrene particles were captured via electrostatic 
interaction by the nanorod and controllably transported at the presence of a Ni segment for 
externally magnetic guidance.35 Since then, assorted Pt based micromotors have been 
fabricated out of different motivations. For instance, Kagan et al. showed for the first time 
the capture, transport and release of doxorubicin (DOX, a broad-spectrum anticancer drug) 
loaded polymeric particles and liposomes by using a similar Au-Pt micromotor. The release 
of such cargo was accomplished by a fast reversal of the micromotors’ motion whereby the 
drag force imposed on the cargo counterbalanced the magnetic attraction from the microrod 
on it.36 In the same year, Solovev et al realized the controlled manipulation and release of 
multiple microscale objects, including cells, by using rolled-up catalytic microengines. These 
microtubes were fabricated based on micro-patterns by 2D lithography. After the patterning, 
Ge, Pt and Ni layers were sequentially deposited as the sacrificial layer, the catalyst layer and 
the magnetic guidance layer, respectively. When the metals coated patterns were immersed 
in water, Ge layer was asymmetrically dissolved so that the residual metal layers were rolled 
by the created tension force. This was the first tubular micromotor and thus opened a way 
to transport cells on demand to build or repair tissues, as now has been shown by several 
groups.37  However, the introduced systems were not ideal for medical applications as they 
relied on the use of toxic H2O2 as fuel for their motion, making it necessary to identify more 
suitable materials and fuels. An alternative material is Mg, which is stable at room 
temperature and can react with water and create bubbles in an efficient manner. The metallic 
form of Mg is biocompatible and its ions are among the most abundant ones in the human 
body, being essential for the function of many organs.38 As an explorative in vivo approach, 
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Wang et al. reported the application of Mg-based microparticles on the treatment of the 
infection in mouse’s stomach. PLGA and chitosan were coated on the microparticles to 
encapsulate clarithromycin, an antibiotic drug. The motor was driven by the gastric acid in 
the stomach. It released clarithromycin during the dissolving of Mg. Although real-time 
tracking and guidance were not performed in the stomach of the mouse, a higher anti-
infection efficacy was achieved compared to the passive microparticles.39 Considering the 
applicability in the acid-free environment in vivo, Al-Ga/Ti was employed as a material 
combination that allows the motion of micromotors in water without the need of toxic fuels. 
This motion principle was based on the continuous hydrogen generation via liquid-metal 
embrittlement in the Al-Ga system, a reaction that happened between the Al alloy and 
water.40 Such micromotors were also able to move in biological media but they exhibited 
a very short lifespan (few minutes). To date, no cargo release has been demonstrated with 
this system. 
Enzymatic micro- and nano-motors can also move with biocompatible fuels such as glucose 
and urease. Here, the enzymes convert the chemical energy into kinetic motion. Since 
Feringa et al. reported the first carbon nanotube driven by enzymatic reactions in 2005,40 
different synthetic structures have been used to immobilize or carry enzymes to react with 
body fluid mimicking environment, leading to self-propulsion via enhanced diffusion or 
bubble formation. Recently, Sanchez’s group reported the use of silicates based mesoporous 
nanomotors which moved in urease-based media relying on enzymatic reaction to carry and 
deliver DOX-HCl onto cancer cells in vitro. The drug-loaded nanomotors were shown more 
effective in killing cancer cells when they were in presence of urea, compared to passive 
carriers, due to the motor kinetics and the ammonia production by the catalytic 
decomposition of urea.41 As a summary, detailed information of chemical micromotors is 
summarized in Table 1.5 
 
Material 
Propulsion 
mechanism 
Guidance 
mechanism 
Cargo(drug) 
Loading 
mechanism 
Target 
Cargo release 
mechanism 
Ref. 
Au/Pt bimetallic 
nanorods 
Catalytic (H2O2) Magnetic 
Biodegradable 
PLGA particles 
Electrostatic – 
Catalytic 
- Drag force 36 
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Hollow Janus particles 
with Au nanoparticles 
and catalase enzyme 
Catalytic (H2O2) Magnetic DOX 
Physical 
absorption 
HeLa cells NIR 42 
Biodegradable BSA/poly-
L-lysine/gelatin and 
enzyme rocket 
Catalytic (H2O2) Magnetic DOX 
Physical 
absorption 
HeLa cells NIR 43 
Mg based particles Catalytic (acid) pH-taxis Antibiotic drug 
Physical 
absorption 
Mouse stomach pH change 44,45 
Hybrid stomatocyte 
nanomotors made of 
block copolymers 
Catalytic (H2O2) - DOX 
Physical 
entrapment 
HeLa cells 
pH-reducing 
agent 
46,47 
PEDOT/MnO2 Janus 
beads 
Catalytic (H2O2) - CPT 
Electrostatic 
interaction 
- - 48 
CaCO3 based particles Catalytic (acid) - 
Coagulation 
factors 
Physical 
absorption 
Bleeding sites pH change 49 
Silicates based 
mesoporous beads 
Catalytic (urea) - DOX 
Physical 
absorption 
HeLa cells Diffusion 41 
 
Table 1. Details of chemical micromotors 
 
 Physical micromotors 
Physically driven micro- and nano-motors are of great interest, especially for biomedical 
applications due to their fuel-free motion, as they can be actuated by external means such as 
magnetic fields, ultrasound and light. Dreyfus fabricated the first physically driven 
micromotor which contains a DNA-linked chain of colloidal magnetic particles as a 
magnetically driven flagellum.50 This microswimmer was moved by oscillating the external 
magnetic field. For a better control on the guidance and geometry of the micromotor, Nelson 
et al. reported a helical micromotor fabricated by lithography. The swimming locomotion of 
this helical motor could be precisely controlled by three orthogonal electromagnetic coil 
pairs.51 In 2014, their group developed a similar helical motor for remote-controlled 
targeted single-cell drug delivery. The micromotor was fabricated by FSTL with a higher 
fineness, facilitating a higher yield and a more precise control. Ni was coated on the surface 
as a magnetic layer to enable the remote guidance by an external rotating magnetic field. 
Calcein, as model drug was loaded on these motors with the help of the encapsulation of 
liposomes. Efficient calcein delivery to a single cell was achieved.52 To broaden the 
application of the physical micromotor, our group previously developed a microhelix by two 
photon lithography toward assisted fertilization. The fineness of this helical motor was so 
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high that it could precisely swim to the specifically selected immotile sperm and capture it. 
When the sperm flagellum was confined in the inner part of the microhelix with the sperm 
head outside, the sperm was thus blocked on the microhelix and transported by it. This work 
can be an alternative method for in vivo artificial fertilization to avoid the oocytes explanting 
in the future.53 However, the above mentioned micromotors controlled by the magnetic field 
always rely on efficient magnetic material and specific responsible structure, restricting the 
diversity of the micromotors. Considering this, researchers are also investigating the 
possibility to drive more different micromotors by other propulsion systems, such as electric 
field, sound field and light field. Certainly, none of them has to work independently. In the 
future, a more skilled micromotor with combined propulsion mechanisms can be envisioned 
to execute tasks in more complicated environments, such as blood and the cavities inside 
organs.  
 Biohybrid micromotors 
Scientists combined the physical micromotors with the biological component initially for the 
purpose to enhance their adaptability to the human body or capacity for drug loading.54 For 
example, Wu et al. encapsulated Fe3O4 nanoparticles into red blood cells (RBCs). The 
fabricated RBC motors were able to be propelled by ultrasound fields and magnetically 
guided in the whole blood. RBC encapsulation largely enhanced the biocompatibility of the 
magnetic particles.55 However, these RBC motors still need the power from the external 
ultrasound field which could be harmful to the other cell organisms in the human body. Some 
microorganisms owning migration abilities were developed to provide the propulsion of 
micromotors. For example, He et al. developed a hybrid neutrophil micromotor system 
which was guided along the chemoattractant gradients secreted by Escherichia coli.56 DOX-
HCl was successfully loaded and transported by this system. However, the maximum velocity 
of this motor was only 0.17 µm/s. This represents the main problem of inactive motion in 
the use of these flagella-free organisms. Such low velocity brings practical difficulty for the 
guidance of these micromotors. The job can be even in vain if the motors were caught by the 
migrating immune cells or flushed away by the environmental fluid. 
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Self-propelled biological structures are intriguing for their ability to adapt and swim in 
complex environments at high speed thanks to their independent propelling systems. For 
instance, flagellated bacteria have been shown as efficient swimmers at the microscale.57 A 
study of bacteria-driven micromotors demonstrated the transport of fluorescent beads. 
These bacteria exhibited a strong preference of swimming towards an L-serine gradient 
without significant speed change. Bacteria-driven motors can be also applied on the delivery 
of anticancer drugs. Taking advantage of the chemotaxis of E. coli, Park et al. refitted bacteria 
to be an active delivery system,58 by coupling with polyelectrolyte multilayer microparticles 
embedded with magnetic nanoparticles. These motile bacteria could be efficiently guided 
targeting breast cancer cells under a chemoattractant gradient or a magnetic field, and 
release preloaded DOX-HCl into them, showing an enhanced DOX-HCl accumulation in the 
targeted cell compared to the immobile microparticles. Some special bacteria with 
connatural guidable system turn out to be more valuable on precise drug delivery. For 
example, the Magnetococcus marinus can load anticancer drugs with the help of liposomes 
and transfer to the desired targeted cancer tissue under the guidance of the magnetic and 
the chemical gradients.59 
Despite the potential that bacteria showed on propelling micromotors, challenges are 
remaining regarding their use in human body. First comes the safety issue. Bacteria are one 
kind of the most infective exogenous organisms. They induce both acute and chronic 
inflammations due to the immunoreactions and the organs injury induced by the infection of 
bacteria. Besides, bacteria ordinarily have self-protection mechanisms, for example the 
endospore structure, to resist the elimination of the immune system and thus help them hide 
in tissue.  After the hidden bacteria are triggered to recover  by exponential proliferation, 
human body could suffer heavier damage.60 Furthermore, any further import of bacteria will 
inevitably bring microbial flora imbalance, which will disorder the functions of the local 
organs or even the whole body.61 In addition of the safety concern, the adaptability of 
bacteria in human body restricts their propulsion, since the body fluids are not suitable 
environment for their motion. The drug loading by bacteria also represents a problem, 
especially for those micromotors relying on the drug encapsulation by bacteria. As bacteria 
have active metabolism, payload drug is not safe, facing the degradation by the metabolic 
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system of the bacteria or the deactivating by secreted substances by the bacteria. Thereupon, 
a microorganism that is adapted in human body and can provide powerful propulsion is thus 
urgently needed. Among others, the sperm is one promising candidate. 
 Sperm-based micromotors 
Sperms, as the male reproductive cells, are highly differentiated cells that are naturally 
optimized to efficiently swim in the female reproductive system. They are thus potential 
candidates for the treatment of cervical cancers and other gynecologic diseases. All 
mammalian sperm consist a head and a flagellum. The head contains densely coiled 
chromosome and very little amount of cytoplasm. On the anterior of the head covers 
acrosome that contains enzymes to penetrate the oocyte and induce fertilization.62 The 
flagellum can be divided in two parts, the tail that can beat by its outer microtubule doublets, 
and the midpiece in which the mitochondria are located to provide the energy source (ATP) 
for the tail beating.63 Hence, the propulsion is generated by the flagellum. Although the size 
and shape of sperm vary in different species, the cellular component and motion mechanism 
are conserved. We use bovine sperm as a model in this dissertation as they are good 
candidates to simulate human sperm with similar paddle-like shape and helical motion 
mode.64,65 As illustrated in Figure 2.7a, the bovine sperm is about 60 µm long including a 10 
µm long head and 50 µm long flagellum. The head is about 5 µm in width and 1 µm in 
thickness. The sperm can swim in corkscrew-like helical motion thanks to the asymmetric 
bending and rolling of the flexible flagellum. The swimming speed of the sperm can be 
approximately 100 µm/s with a propulsion force up to 128 pN,66 enabling the sperm to be 
promising power supply for micromotors.67 
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Figure 2.7. (a) Structure of a bovine sperm. (b) SEM of the tubular spermbot (scale bar: 5 
µm).68 Reproduced with permission from © 2016 WILEY‐VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
Magdanz et al. fabricated the first sperm hybrid micromotor based on a rolled-up method in 
2013.68 The so-called spermbot comprises of a bovine sperm as propulsion mechanism and 
an artificial microtube as guidance mechanism (Figure 2.7b). The magnetic microtube was 
constructed by a nanolayer of Fe which was deposited on the patterned photoresist with a 
sacrificial layer by lithography. After the sacrificial layer was dissolved in water, the Fe layer 
was rolled-up into a conical tube by the tension force. The sperm was then able to be stuck 
in and propel it forward. This system showed its value on single sperm transport and its 
further potential on assisted fertilization toward oligospermia. The coupling efficiency of 
sperm and microtubes could be further increased with the help of a fibronectin coating or 
simply narrowing the tube.69 To improve this system furthermore, they fabricated a PNIPAM 
microtube, a thermal-responsive polymer, to control the release of the sperm. They showed 
a 
b 
 22 
 
that the sperm release could be triggered by increasing the temperature from 37 to 40 
degree.70 
Regarding the application on drug delivery, the sperm features unique properties 
advantageous over the other artificial or cellular carriers. First, the sperm has powerful 
propulsion force that facilitates a fast and efficient delivery. The propulsion of the sperm 
needs neither toxic fuels nor external power source that is harmful to body. It in fact does 
not need any fuel from the environment when all the energy is generated out of the stored 
fuel by its own mitochondria. The highly independent self-propulsion broadens its 
applicable environments. Second, the sperm provides a possibility to efficiently encapsulate 
hydrophilic drugs, which have high DNA-binding affinity71 and thus can be stored in the 
crystalline nucleus of the sperm.72 By doing so, the sperm membrane can protect drugs from 
body fluid dilution, immune-reactions and the degradation by enzymes. sperm can also 
efficiently avoid dose dumping, which is regarded as a major issue of micelle carriers, thanks 
to their compact membrane system.73 Moreover, for microscale synthetic carriers such as 
microspheres, micro capsules, and drug-loaded micromotors74–76  drug transfer is always a 
problematic issue due to the inefficient transmembrane transport between the carrier and 
the cell.77 In contrast, sperm cells, with their somatic cell-fusion ability,78–80 are expected to 
improve the drug transfer to the target cells as well as the drug availability, by directly 
delivering the drug into the targeted cell plasm through membrane-fusion events. Several 
proteins of the sperm membrane such as CD9 and integrins are involved in this process.78 In 
the end, sperm do not proliferate or secret any harmful substance, ensuring the safety of the 
hybrid micromotors in the in vivo use. All of these make the sperm an excellent choice to 
construct new biohybrid micromotors and thus make this sperm-motor to be a promising 
candidate for the next-generation active drug delivery system. 
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3. Materials and methods 
 Fabrication of microstructures 
The fabrication of the microstructures were done by a two-photon lithography technique 
(Nanoscribe).  A console software naming Nanowrite was used to for the inner 
communication of the designed 3D file with the lithography machine. Its complier can read 
3D CAD files generated by, for example Solidworks or other 3D modeling softwares. However, 
a more efficient way is to code the laser path with specific functions and all the parameters 
manually, avoiding redundant exposure. The writing process can be all directed by the codes 
by guiding the laser to expose at certain locations with certain power for certain time. The 
work flow is as following: designing the purposed structure, coding the laser path with 
appropriate functions, optimizing the writing parameters, preparing photoresist and 
constructing the structure.21 In this dissertation, we mainly introduce three different 
microstructures, the microtetrapod, the streamline-horned cap (SHC) and the helical 
microcourier (MC).  
3.1.1. Coding 
The manufacturing codes were written by Describe. Galvo scanning mode was used to write 
the main parts of all three structures.  
 The microtetrapod is assembled by two parts. A tubular body and four curved arms 
(as shown in Figure 3.1). The tubular body is formulated as: 
𝑥 = 5.3𝑠𝑖𝑛𝜃 
𝑦 = 5.3𝑐𝑜𝑠𝜃 
𝑧 = ℎ1 
𝜃𝜖(0, 2𝜋), ℎ1𝜖(0, 15), 
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where (𝑥, 𝑦, 𝑧)  represents the positioning of the exposure spot, h1 represents the 
independent variable limited by the tube height and θ represents the independent variable 
limited by the angle of the writing position in polar coordinates system. Here the laser power 
of exposure is 10 mW, the exposure time is 50 fs and the scan speed of the galvo is 80000 
µm/s. 
The curved arm is formulated as: 
𝑥1 =
(
 
 
7.5 −
ℎ2
𝑡𝑎𝑛 (𝑎𝑟𝑐𝑠𝑖𝑛√
ℎ2
15))
 
 
∗ 𝑐𝑜𝑠 (𝜑 −
𝜋
6
) 
𝑥2 =
(
 
 
7.5 −
ℎ2
𝑡𝑎𝑛 (𝑎𝑟𝑐𝑠𝑖𝑛√
ℎ2
15))
 
 
∗ 𝑐𝑜𝑠 (𝜑 +
𝜋
6
) 
𝑦1 =
(
 
 
7.5 −
ℎ2
𝑡𝑎𝑛 (𝑎𝑟𝑐𝑠𝑖𝑛√
ℎ2
15))
 
 
∗ 𝑠𝑖𝑛 (𝜑 −
𝜋
6
) 
𝑦2 =
(
 
 
7.5 −
ℎ2
𝑡𝑎𝑛 (𝑎𝑟𝑐𝑠𝑖𝑛√
ℎ2
15))
 
 
∗ 𝑠𝑖𝑛 (𝜑 +
𝜋
6
) 
𝑧 = ℎ2 
𝜑 = {0,
𝜋
2
, 𝜋,
3𝜋
2,
}, ℎ2𝜖(0, 14) 
where (𝑥, 𝑦, 𝑧) {𝑥𝜖(𝑥1, 𝑥2), 𝑦𝜖(𝑦1, 𝑦2)} represents the positioning of the exposure spot, h2 
represents the independent variable limited by the arm height and φ  represents the 
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independent variable limited by the phase angle of each arm. Here the laser power of 
exposure is 9 mW, the exposure time is 50 fs and the scan speed of the galvo is 60000 µm/s. 
 
 
 
Figure 3.1. Design of the microtetrapod 
 
 The SHC is assembled by two parts. An ellipsoid body and a tapered horn (as shown 
in Figure 3.2). The ellipsoid body is formulated as: 
𝑥 = 6.5𝑐𝑜𝑠𝜃 ∗ √1 −
ℎ1
2
169
 
𝑦 = 6.5𝑠𝑖𝑛𝜃 ∗ √1 −
ℎ1
2
169
 
𝑧 = ℎ1 
𝜃𝜖(0, 2𝜋), ℎ1𝜖(0, 12), 
Isometric 
Side 
Top 
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where (𝑥, 𝑦, 𝑧)  represents the positioning of the exposure spot, h1 represents the 
independent variable limited by the tube height and θ represents the independent variable 
limited by the angle of the writing position in polar coordinates system. 
The tapered horn is formulated as: 
𝑥 = 𝑐𝑜𝑠𝜑 ∗ √1 −
ℎ2
3
 
𝑦 = 𝑠𝑖𝑛𝜑 ∗ √1 −
ℎ2
3
 
𝑧 = ℎ2 
𝜑𝜖(0, 2𝜋), ℎ2𝜖(0, 3), 
where (𝑥, 𝑦, 𝑧)  represents the positioning of the exposure spot, h2 represents the 
independent variable limited by the horn height and φ represents the independent variable 
limited by the angle of the writing position in polar coordinates system. The laser power of 
exposure for the whole structure is 10 mW, the exposure time is 50 fs and the scan speed of 
the galvo is 60000 µm/s. 
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Figure 3.2. Design of the SHC. 
 
 The MC is assembled by three parts. A tubular body, a cross frame and a helical tail 
(as shown in Figure 3.3). The tubular body is formulated as: 
𝑥 = 40𝑠𝑖𝑛𝜃 
𝑦 = 40𝑐𝑜𝑠𝜃 
𝑧 = ℎ1 
𝜃𝜖(0, 2𝜋), ℎ1𝜖(0, 30), 
where (𝑥, 𝑦, 𝑧)  represents the positioning of the exposure spot, h1 represents the 
independent variable limited by the tube height and θ represents the independent variable 
limited by the angle of the writing position in polar coordinates system. Here the laser power 
of exposure is 10 mW, the exposure time is 50 fs and the scan speed of the galvo is 80000 
µm/s. 
The cross frame is  
𝑥1 = −20𝑠𝑖𝑛𝜎 
𝑥2 = 20𝑠𝑖𝑛𝜎 
Isometric Side 
Top 
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𝑦1 = −20𝑐𝑜𝑠𝜎 
𝑦2 = 20𝑐𝑜𝑠𝜎 
𝑧 = 0 
𝜎 = {0,
𝜋
2
}, 
where (𝑥, 𝑦, 𝑧) {𝑥𝜖(𝑥1, 𝑥2), 𝑦𝜖(𝑦1, 𝑦2)} represents the positioning of the exposure spot 𝜎 
represents the independent variable limited by the angle of the writing position in polar 
coordinates system. Here the laser power of exposure is 12 mW, the exposure time is 50 fs 
and the scan speed of the galvo is 60000 µm/s. 
The helical tail is formulated as: 
𝑥1 = 30𝑐𝑜𝑠 (
ℎ2
2𝜋
) 
𝑥2 = 30 𝑐𝑜𝑠 (
ℎ2
2𝜋
+ 1) + 1.5 
𝑦1 = 30𝑠𝑖𝑛(
ℎ2
2𝜋
) 
𝑦2 = 30𝑠𝑖𝑛 (
ℎ2
2𝜋
+ 1) + 1.5 
𝑧 = ℎ2 
ℎ2𝜖(0, 120), 
where (𝑥, 𝑦, 𝑧) {𝑥𝜖(𝑥1, 𝑥2), 𝑦𝜖(𝑦1, 𝑦2)} represents the positioning of the exposure spot, h2 
represents the independent variable limited by the tail. Here the laser power of exposure is 
2 mW, the exposure time is 50 fs and the scan speed of the galvo is 80000 µm/s. 
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Figure 3.3. Design of the microcourier. 
 
3.1.2. FSTL manufacturing 
SiO2 substrate were cleaned by nonpolar and polar organic solvents under ultrasound in 
sequence. Then the dried substrate was exposed to O2 plasma for 1 min to enhance the 
wettability of the surface. Photoresist IP-DIP was dropped on the substrate and the objective 
was dipped into the photoresist. The interface between the substrate and the resist as the 
starting point of writing was detected with the signal amplitude at 50% and the exposure 
rate of the signal capturing by the autofocus camera at 70%. After writing, the sample was 
developed in propylene glycol methyl ether acetate (PEGMA) for 20 min and washed in 
isopropanol for 3 min to remove the residual IP-DIP. Finally, the sample was dried in a 
critical point dryer ((CPD, Autosamdri®-931, Tousimis Research Corporation) to avoid 
structure transformation by the tension force during drying. 
3.1.3. Electron beam evaporation 
Electron beam evaporation (E-beam), as a type of physical vapor deposition, is widely used 
to generate thin films at the nanoscale.81 During the deposition process, an electron beam is 
Isometric 
Side 
Top 
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generated by an electron gun to bombard the target material. Atoms of the target can be 
transformed then into gaseous phase and re-precipitate on the substrate surface at a certain 
low rate, ranging from 0.1 to 10 Å/s. The deposition thickness is monitored by a quart crystal 
microbalance. The deposition rate can be then controlled by changing the heating current. 
The whole deposition is performed in a high vacuum chamber to avoid oxidation and any 
other chemical reactions. In this dissertation, an e-beam evaporator Edwards auto 500 e-
beam (Moorfield Nanotechnology Limited) was used for the deposition. Ti, Fe, Au and SiO2 
of high purity (99.995 %) were used separately for different purposes. The heating voltage 
was set at 5 KV and the heating current was set at around 80, 70, 50 and 10 mA , separately 
for Ti, Fe, Au and Si2, inducing deposition rates at 3, 1, 1, 1 Å/s. 
As an example of the fabrication of the artificial microstructures, Figure 3.4 illustrates the 
whole process of the fabrication of microtetrapods. 
 
Figure 3.4. Fabrication of microtetrapods 
 
 Fabrication of microfluidic chips 
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Microfluidic chips are widely used in the study of micromotors to visualize the motion and 
precisely control the flow. In our research, polydimethylsiloxane (PDMS) microchannels 
were used to provide a confined space with clear visualization to monitor the swimming 
behavior of the micromotors, culture cancer cells at the microliter scale and control the flow 
rate. The fabrication was done by a molding method as exhibited in Figure 3.5.  PDMS gel 
was plasticized on the mold to duplicate channels with the reversed shape. Finally, the 
channels were bound to clean glass or silicon wafers to obtain the microfluidic chips with 
channel thickness from 10 to 1000 µm. The molds were manufactured based on a maskless 
lithography method on a negative photoresist. First, a layer of photoresist SU-8 2075 was 
spin-coated on a silicon wafer with specific thickness adjusted by the spin speed. After 
essential pre-bake to evaporate the solvent, the lithography was done by a direct laser 
writing machine (MLA), which applies a focused laser beam to selectively expose the desired 
area according to a 2D CAD design. The UV exposure decomposes the initiator and creates 
the active photoacid.82 A direct post-bake was employed immediately after laser writing to 
induce the polymerization of the photoresist in the exposed area with photoacid. Then the 
sample was developed in acetone and baked again to enhance its stability.   
PDMS prepolymer was prepared with the base and curing agent at a ratio of 10:1. After 30 
min of degassing, the mixture was filled in the mold and baked at 75 °C for 3 hours. After that, 
the polymerized PDMS channel was peeled off and punched into corresponding inlets and 
outlets. Finally, the PDMS channel and a glass slide substrate were treated in O2 plasma for 
1 min and then bound together by a silicon oxygen bond83 created at 90 °C for 20 min. 
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Figure 3.5. PDMS channel fabrication 
 
 Liposomes immobilization 
Unilamellar liposomes were prepared by using a mini liposome extruder (Avanti). Briefly, 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and cholesterol at a weight ratio 
of 4:1 were fully mixed and dried under the protection of nitrogen flow. After that, the 
mixture was dispersed in heparin sodium salt (Alfa Aesar) solution at a concentration of 50 
mg/mL and extruded at 60 ℃. The liposomes immobilization was accomplished by an 
improved method from the literature.59,84 First, the microcaps were carboxylated by 
carboxyethylsilanetriol (abcr). And then they were incubated in the liposome solution with 
the presence of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC) / N-
Hydroxysuccinimide (NHS) at 37℃. After that, the sample was washed by water for three 
times and dried in a critical point drier.  
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 Drug loading in sperm 
3.4.1. Sperm preparation 
 Preparation of bovine sperm samples:  
Bovine sperm cells were recovered by thawing cryopreserved sperm straws rapidly in a 
water bath at 38 °C for 2 min, and washed with BoviPure 100 / BoviDilute (40%/ 80%) by 
centrifugation at 300g in soft mode for 5 min.85 After the third centrifugation, 100 µL SP-
TALP was gently added on the sperm pellet to induce a swim-up selection. After 40 min of 
incubation, the top liquid containing motile sperm was extracted out and diluted by SP-TALP 
to 1 mL for subsequent use. 
 Preparation of human sperm samples 
Human sperm samples were obtained from patients attending the Department of 
Reproductive Medicine, St Mary’s Hospital, Manchester for routine fertility treatment, 
following written informed patient consent with approval from the Yorkshire & The 
Humber-Bradford Leeds Research Ethics Committee (18/YH/0130). Samples were washed 
with SPERMRINSE™ (Vitrolife) and suspended in G-IVF™ PLUS medium (Vitrolife). 
SPERMGRAD™ (Vitrolife) was used to separate progressively motile sperm out by density 
gradient centrifugation according to the G-Series Manual (Vitrolife). After purification, 
sperm samples were stored at room temperature for subsequent use. 
3.4.2. Drug loading process 
Figure 3.6 illustrates the loading process in sperm. In the following Chapter 4 and 5, DOX-
HCl is used as a model drug to evaluate the encapsulation performance of sperm cells. DOX-
HCl is a widely approved chemotherapeutic medication with a broad application spectrum 
in cancer therapy since 1974.86 Its liposomal form (Doxil) is also used primarily for 
gynecologic cancer treatment.87  Fluorescein isothiocyanate conjugated bovine serum 
albumin (FITC-BSA) is used as a non-toxic control model. Briefly, 1 mg/mL of FITC-BSA 
(Sigma-Aldrich, Germany) and DOX-HCl (Sigma-Aldrich, Germany) solution were prepared 
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in SP-TALP, respectively, and stored under dark conditions at 4 °C as stock solutions. To 
prepare DOX/BSA-loaded sperm cells, a mixture of sperm solution and FITC-BSA or DOX-HCl 
solution at specific concentrations were co-incubated in a humidified atmosphere of 5% CO2 
in air at 37 °C for 1 h. After washing the sample 2 times with SP-TALP by centrifugation at 
300 g for 5 min, the pellet of drug-loaded sperm was redispersed in SP-TALP with 
progesterone (20 ng/mL) and stored in the incubator under dark conditions for subsequent 
use. It is important to note that the samples were to be used within 4 h to guarantee sperm 
motility. 
For the DOX-HCl loading in human sperm, the incubation was done at room temperature for 
40 min. 
 
Figure 3.6. DOX-HCl loading in sperm 
3.4.3. Evaluation of the drug loading efficiency 
The success of the drug loading procedure was evaluated by the determination of the 
encapsulation efficiency. DOX-HCl-loaded sperm were prepared as mentioned before with a 
concentration of 3×106 sperm per mL. The samples of DOX-HCl solution were designed as a 
series of concentrations with 10, 20, 50, 100 and 200 µg/mL. FITC-BSA-loaded sperm were 
prepared with FITC-BSA solution with a concentration of 100 µg/mL. After incubation of 
sperm in these solutions, the respective supernatant was collected after centrifugation and 
filtered through a 2 µm pore size membrane. The sperm were resuspended after purification 
as mentioned before. Fluorescence images were taken at an excitation wavelength of 470 nm 
(DOX-HCl: Ex 470 nm, Em 580 nm;88 FITC-BSA: Ex 470 nm. Em 509 nm89) (Cell Observer, 
Carl Zeiss Microscopy GmbH).  
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 Indirect method for bovine sperm evaluation  
In this method, the concentration of DOX-HCl was determined with a fluorescence 
spectrometer in FL-RL mode (SpectraMax® M2, Molecular Devices, LLC.). SP-TALP solution 
was used as blank control for all measurements. The concentration of the residual DOX-HCl 
was determined by measuring the supernatant of each sample after centrifugation.90  The 
encapsulation efficiency was calculated as the ratio of encapsulated drug to the total amount 
of the used drug: 
𝐷𝑂𝑋 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑟𝑎𝑡𝑖𝑜 =
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑠𝑒𝑑 𝐷𝑂𝑋 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝐷𝑂𝑋
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑠𝑒𝑑 𝑑𝑟𝑢𝑔
 
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑠𝑝𝑒𝑟𝑚 =
𝑡𝑜𝑡𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑢𝑠𝑒𝑑 𝑠𝑝𝑒𝑟𝑚𝑠
 
The drug loading amount was determined by the difference between the initial amount of 
DOX-HCl before incubation and the residual amount in the supernatant after co-incubation, 
which were both quantified by their respective fluorescence signals. 
 Direct method for human sperm evaluation  
In this method, amount of the encapsulated DOX-HCl was directly determined by lysing the 
sperm. DOX-HCl loaded human sperm were lysed for 30 mins in Triton-X 100 (20%). The 
mixture was then incubated in acidified isopropanol (0.75 N HCl) at 4 C over night. After 
that, the samples were centrifuged at 12000g for 10 minutes and the released DOX-HCl in 
the supernatant was determined with a fluorescence spectrometer as mentioned before 
while the acidified isopropanol with sperm lysate as blank control.91 DOX-HCl solution was 
dissolved in acidified isopropanol with sperm lysate to depict standard curve. The 
encapsulation efficiency was calculated as: 
𝐷𝑂𝑋 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑟𝑎𝑡𝑖𝑜 =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑑𝑟𝑢𝑔 
𝑡𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑠𝑒𝑑 𝑑𝑟𝑢𝑔
 
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑠𝑝𝑒𝑟𝑚 =
𝑡𝑜𝑡𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑢𝑠𝑒𝑑 𝑠𝑝𝑒𝑟𝑚𝑠
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3.4.4. Evaluation of encapsulation stability 
The encapsulation stability test was carried out by calculating the accumulative release ratio 
of DOX-HCl from sperm into SP-TALP. Drug-loaded sperm were incubated in SP-TALP in a 
dark place under humidified atmosphere, 5% CO2 and 37°C. At each time point, the samples 
were centrifuged and 0.5 ml of supernatant was collected and replaced with 0.5 ml of SP-
TALP. After 96 hours, the samples was treated with ethylene diamine tetraacetic acid 
(EDTA)-Trypsin for 3 mins to release all drug into the solution. Fluorescence spectroscopy 
was used to quantify the DOX-HCl concentration of the supernatant. The accumulative 
release ratio was calculated as the ratio of the accumulated amount of the drug to the total 
amount of it. SP-TALP was used as blank control. 
3.4.5. Evaluation of the sperm viability after drug loading 
DOX-HCl-loaded sperm were prepared as mentioned before by incubating sperm (8×105 sperm 
in 1 mL) with DOX-HCl at a concentration of 100 µg/mL. After purification, sperm were 
incubated in a humidified atmosphere of 5% CO2 in air at 37 °C. After specific time periods, 
drug-loaded sperm were analyzed by fluorescence microscopy (Cell Observer, Carl Zeiss 
Microscopy GmbH), using a commercial LIVE/DEAD Viability Kit (ThermoFisher). Briefly, 
sperm solution (106 sperm) were incubated with 5 µL of diluted Component A (SYBR 14, 10%) 
for 10 min and 5 µL of Component B (propidium iodide) for 5 min, respectively. After 
washing, sperm analysis was performed at an excitation wavelength of 470 nm to visualize 
the live sperm.  
3.4.6. Evaluation of the motility of DOX-HCl-loaded sperm 
DOX-HCl-loaded sperm were prepared as mentioned before. Unloaded sperm were treated 
with the same method as the control sample. After purification, sperm were incubated in SP-
TALP in a humidified atmosphere of 5% CO2 in air at 37 °C.  At certain time points along 36 
h, 100 µL of sperm (104 per each sample) was extracted from the Petri dish and added into 
the counting chamber to study the motility. For that, a computer-assisted sperm analysis 
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(CASA) system (AndroVision®, Minitube GmbH) was employed. 10 fields (ca. 500 sperm) of 
each sample were counted at each time point. 
 
 Cancer cell culture 
3.5.1. Culture of HeLa cells and spheroids 
HeLa cells were cultured at 37°C in a humidified atmosphere containing 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin.92 For spheroids culture, 
HeLa cells were recovered and maintained for 2 weeks before use. To prepare spheroids 
with homogeneous sizes, equal amounts of HeLa cells (2 × 105 cells resuspended in 4 mL) 
were added to 3.5-cm cell-repellent dishes (Greiner bio-one) after trypsinization and PBS 
washing. After two days of maturation, spheroids were separated in different groups and 
incubated with related treatments. 
3.5.2. HGSOC-representative ex vivo tumour cell culture and spheroids 
OCMI66 cells were provided by Stephen Taylor. In brief, from ascites, red blood cells were 
lysed, the remaining cellular fraction harvested by centrifugation, and the cells maintained 
in OCMI media93 in 5% O2 and 5% CO2 at 37°C in a humidified atmosphere. Serial passaging 
and selective detachment was used to eliminate white blood cells and separate tumour 
fractions from stromal cells. Experiments were performed at early passage numbers (p20s). 
The OCMI66 culture has been previously characterised including drug sensitivities (Nelson 
et al., has been submitted). The project is covered by an MCRC Biobank license held by 
Stephen Taylor (16_STTA_01). OCMI66 spheroids were prepared as for HeLa cells (see 
above). 
3.5.3. Evaluation of antitumor efficacy of DOX-HCl loaded sperm 
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DOX-HCl-loaded sperm were prepared as mentioned before by incubating blank sperm 
(8×105 sperm in 1 mL) with DOX-HCl at a concentration of 100 µg/mL. After purification, 100 
µL of sperm solution (8×104 sperm) was added into HeLa spheroids suspension (4 mL) and 
co-incubated in a humidified atmosphere of 5% CO2 in air at 37 °C. Spheroid control was 
prepared by adding 100 µL of SP-TALP while blank sperm control was prepared by adding 
100 µL of blank sperm solution (8×104 sperm). DOX-HCl solution control was prepared by 
incubating HeLa spheroids with 100 µL of DOX-HCl solution at a concentration of 15 µg/mL. 
The LIVE/DEAD Viability Kit (ThermoFisher) was employed to stain cells and analyze the 
cell viability. Briefly, HeLa spheroids were washed and digested by trypsin-EDTA to a single-
cell suspension at certain time points. After that, cells were incubated with 1 µl of Component 
A (SYBR 14) for 10 mins and 5 µl of Component B (propidium iodide) for 5 mins, respectively. 
Cell counting was performed under excitation at the wavelength of 470 nm for live cells and 
540 nm for dead cells (4 samples for each group, 104 cells for each sample) (Cell Observer, 
Carl Zeiss Microscopy GmbH).  
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4. Tetrapod-like sperm-motor for targeted drug delivery 
This chapter is based on the publication titled: Sperm-hybrid micromotor for targeted drug 
delivery. Reprinted with permission from [ACS Nano 2018, 12, 1, 327–337] 
(doi/10.1021/acsnano.7b06398). Copyright [2018] American Chemical Society. 
 Background 
The development of drug delivery systems that provide effective doses locally in a controlled 
way is one of the main goals in the worldwide fight against cancer.94,95 The current challenges 
include the unspecific uptake by other organs,6 limited tissue penetration8 and the decrease 
of effective concentration due to the dilution in body fluids.7 Among the most promising 
nano- and microcarriers approaches to overcome such hurdles are cellular drug delivery 
systems, where a cell or microorganism acts as drug carrier, as they have advantages like cell 
membrane fluidity, ability to interact with other cells/tissue, long lifespan and high 
biocompatibility.96 Stem cells, for example, have been used as a combinatorial drug delivery 
system towards regenerative therapy.97 Macrophages and red blood cells with and without 
synthetic guidance or propulsion components have also been suggested as carriers for 
cancer therapy98 and sustained drug release in blood,99 respectively. Likewise, self-propelled 
cells, as a combination of cellular encapsulation and propulsion, have interested scientists 
all over the world due to their swimming performance in complex physiological 
microenvironments.68,100 For example, magneto-aerotactic bacteria were reported to deliver 
drug-loaded liposomes to the hypoxic regions of tumor tissue in mice.59 Bacteria, with 
chemotactic101 properties and/or with associated synthetic guidance components,102–104 can 
transport and deliver drugs into tumor tissue, showing great potential as self-propelled drug 
delivery carriers. Nonetheless, it is noteworthy that rapid clearance or even autoimmune 
reactions might be caused by the immune response to certain bacteria.105  
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Compared to other cellular drug carriers, sperm are promising candidates for the treatment 
of gynecologic diseases due to their environmental adaptability, their encapsulation and 
protection ability to drug and their somatic cell-fusion ability, as summarized in Section 2.3. 
Previous research demonstrated the use of sperm as carriers of nanoparticles106 and lipid 
vesicles107 on the sperm membrane for protein localization and potential biomacromolecule 
transport, respectively. In this chapter, we present a tetrapod-like sperm-motor for targeted 
drug delivery. This system comprises a motile sperm cell as the propulsion source and drug 
carrier, and the microtetrapod featuring four arms which release the sperm cell in situ when 
they are bent upon pushing against a tumor spheroid. Providing controllable guiding and 
release mechanisms, the tetrapod-like sperm-motor can potentially deliver drug to tumor 
cells and furthermore avoid undesired drug accumulation in healthy tissue. This system 
combines several intriguing features, namely high drug loading capacity, self-propulsion, in 
situ mechanical trigger release of the drug-loaded sperm, sperm penetration ability and 
improved drug availability.  
 Drug loading in sperm 
In this chapter, DOX, as a model drug, was loaded in bovine sperm by co-incubation of DOX-
HCl and live sperm, as described in Section 3.4.2. After purification, the incubated sperm 
sample was redispersed in the sperm medium. The drug-loading of sperm was evaluated by 
fluorescence microscopy as shown in Figure 4.1a, as DOX-HCl exhibits self-fluorescence at 
470 nm excitation wavelength. It was calculated that 98% of the sperm cells (ca. 3500 sperm 
cells) were loaded with DOX-HCl. DOX-HCl was predominately found in the head of sperm as 
can be seen in Figure 4.1a(ii). A 3D reconstructed image, obtained from overlaid z-stack 
images of a single sperm cell is shown in Figure 4.1a(iii), indicating that DOX-HCl was 
mainly loaded inside the sperm head. This can be attributed to the drug adsorption on the 
condensed chromosomes by binding to proteasomes108 and the drug dispersion in the 
cytoplasm that remains in the head of the sperm after maturation.63,106 As a complementary 
experiment, we loaded sperm with Fluorescein isothiocyanate labelled bovine serum 
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albumin (FITC-BSA), a model for protein drugs as an alternative control. In this case, sperm 
behaved differently from the loading of DOX-HCl. FITC-BSA accumulation occurred all over 
the sperm, including head, midpiece and tail (Figure 4.1b). 
 
Figure 4.1. sperm loaded with (a) DOX-HCl; (b) FITC-BSA. (i), (ii), (iii) represent 10×, 40× 
and 3D reconstruction of z-stack images. 
 
The loading efficiency was measured by fluorescence spectrometry, as described in the 3.4.3. 
The encapsulation efficiency was calculated as the ratio of encapsulated drug to the total 
amount of the used drug. The drug loading amount was determined by the difference 
between the initial amount of DOX-HCl before incubation and the residual amount in the 
supernatant after co-incubation, which were both quantified by their respective 
a 
b 
i ii 
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i 
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fluorescence signals. Figure 4.2 depicts the drug loading profiles related to DOX-HCl 
concentration. In the solution with a concentration of 3×106 sperm per mL, the loading 
amount of DOX-HCl increased approximatively linearly with the concentration of DOX-HCl 
ranging from 10 to 200 µg/mL. Hence, the loading ratio remains at around 15% for all 
concentrations. For the maximum concentration of DOX-HCl in our experiments, the loading 
amount was up to 37 µg in 500 µL sperm solution. This amount indicates an average 
encapsulation of 15 pg of DOX-HCl per single sperm cell.  
The result of the drug loading ratio calculation highlights the high encapsulation capacity of 
sperm cells. Previously, Munerati et al reported successful loading of DOX-HCl into 
macrophages. Similar to our results, DOX-HCl was found inside the cell (2.5 pg per cell), 
particularly in the nucleus, with a higher concentration compared to the residual DOX-HCl 
solution in the culture medium (cell size roughly 15-20 µm). To explain this loading profile, 
the authors referred to the adenosine triphosphate (ATP)-mediated permeabilization of cells 
as a possible encapsulation mechanism.109 In our research, DOX-HCl was used because cells 
also exhibit improved uptake of ionic DOX-HCl110 compared to molecular DOX, which is 
normally taken in by facilitated diffusion.86 This could allow the use of high local doses of 
anticancer drugs while reducing systemic toxic effects. Further research is required to 
investigate in detail the transport mechanism through the sperm membrane.  
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Figure 4.2. Encapsulation efficiency of DOX-HCl in sperm. 
 
In order to analyze the influence of DOX-HCl on sperm, two complementary tests were 
performed. First, the viability of DOX-HCl-loaded sperm was analyzed using a commercial 
LIVE/DEAD kit. No significant difference was observed compared to unloaded sperm as 
more than 30% of sperm were still alive in both cases after 4 hours of culture in SP-TALP. As 
a more direct study to determine the most apt sperm for the intended goal of drug delivery, 
sperm motility test was suggested, as it not only provided information about sperm viability 
but also about their ability to transport the drug. Figure 4.3a shows the motility change of 
sperm after the loading process of DOX-HCl at 100 μg/mL. A control sample with unloaded 
sperm was incubated in SP-TALP without drug under the same incubation and purification 
conditions. Motilities of both sperm samples decreased over time similarly. In the first 4 h, 
the percentage of motile sperm decreased from ca. 56% to 36%, which is however still 
sufficient enough to couple with the micromotors for the subsequent experiments. After 8 h 
of incubation, ca. 25% of sperm were still motile in both groups. Thus, we suggest to perform 
the drug-delivery experiment within 8 h after the drug-loaded sperm are prepared, which is 
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sufficient to reach any organ from the reproductive system (the maximum traveling distance 
is about 144 cm, considering an average velocity of the sperm-hybrid micromotor of 50 
µm/s). Thus, the influence of DOX-HCl on sperm viability is not significant. This can be 
explained by the fact that DOX-HCl kills cancer cells by interfering with their macromolecular 
biosynthesis.111 Unlike cancer cells, mature sperm have terminated most of their 
macromolecular synthesis due to the lack of a complete endomembrane system.112 The 
propelling power is all generated in the mitochondria in the sperm’s midpiece.63 Therefore, 
taking account of the observation that the velocity significantly decreased when the DOX-HCl 
concentration was higher than 100 µg/ml (probably due to the membrane destruction by 
the high osmotic pressure), we used a concentration of 100 µg/mL DOX-HCl to load the 
sperm for the subsequent experiments. Another advantage of sperm comes from their 
incomplete metabolic system,112 as sperm can protect a contained drug within its lipid 
bilayer like a liposome, but does not metabolize it like stem cells or other somatic cells would 
do. We also carried out a test on the encapsulation stability. The results show that less than 
10% of drug was leaked into the medium after 8 h (Figure 4.3b). This means that the DOX-
HCl encapsulation by sperm is sufficiently stable for subsequent drug delivery experiments. 
 
 
Figure 4.3. (a) Sperm motility after drug loading. (b) Stability of DOX-HCl loading in sperm. 
 
a b 
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 Sperm-motor transport 
The microtetrapods were fabricated in an array with 14400 structures on a substrate at 2×2 
cm2. The dimensions of the microstructure are shown in Figure 4.4a. At the narrowest point 
between the four arms, the maximum distance is 4.3 µm. In preliminary experiments, the 
dimensions of the structure were optimized according to the dimensions of the sperm cell 
(for the experiments shown in this chapter, bovine sperm cells were selected for their 
paddle-like shape similar to human sperm), of which the head is on average 4.5 µm wide, 1 
µm thick and 10 µm long (Figure 4.4b). Figure 4.4c shows the finite element simulation 
validating the bending capability of the microtetrapod geometry. By calculation, when a 
force of about 128 pN (average sperm force obtained from literature)66 was applied to one 
of the arms, the resulting displacement was 116 nm, which was enough to release the sperm. 
The displacement would increase up to 407 nm when the applied force is 450 pN, which 
could be generated by a hyperactivated sperm (which exhibits higher tail amplitude and 
asymmetric beating pattern).66 
 
 
Figure 4.4. Geometry of the microtetrapod. (a) SEM images. (b) Top view of the 
microtetrapod with schematic sperm head inside. (c) Finite element analysis results 
demonstrating the deformation of one single arm. Yellow arrows represent the applied 
forces. (i) 128 pN from a motile, non-hyperactivated sperm, and (ii) 450pN from a 
hyperactivated sperm.  
 
b a c 
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 When a sperm reaches a tetrapod, it gets mechanically trapped inside the cavity of the 
tubular part and starts to push the microtetrapod forward. The tubular body of the 
microtetrapod is only 2 µm longer than the sperm head, thus the sperm tail can still beat 
freely outside the tube to provide powerful propulsion.69 Compared to free sperm, the 
average swimming velocity of the sperm-hybrid motors is nonetheless decreased by 43% 
from 73 ± 16 µm/s to 41 ± 10 µm/s (average of 15 samples of sperm-hybrid motors). All 
measurements were performed in SP-TALP at room temperature. Despite the variability 
among different sperm samples, the main reason for the velocity reduction is thought to be 
the increase of the fluid drag that is provoked by the synthetic material and the complex 
structure of the tetrapod. The asymmetrically distributed metal coating makes it possible to 
guide the microtetrapod or the tetrapod-like sperm-motor. Figure 4.5a illustrates a 
rectangular track of a guided sperm-hybrid motor. The hybrid motor was easily steered by 
changing the direction of the external magnet. After coupling to a tetrapod, the sperm still 
rotated when the hybrid motor moves forward due to the helical motion of the sperm,113 
which means the microtetrapod did not change the characteristic motion of the coupled 
sperm. The vertical guidance of a sperm-tetrapod is shown also in Figure 4.5b. The sperm-
hybrid motor was steered to swim vertically out of plane simply by tilting the external 
magnet vertically. Before starting the experiments with sperm cells, tetrapods were always 
treated with Pluronic® F-127 solution to reduce undesired adhesion114 between the sperm 
membrane and the microtetrapod surface.  
PDMS microfluidic channels were fabricated as a platform for the investigation of the sperm 
release mechanism. Figure 4.5c shows the sperm escape when the sperm-motor hit a wall. 
The majority of tetrapods was found to rotate together with captured sperm due to either 
surface interaction between the sperm membrane and the material surface or the 
mechanical locking of the sperm head inside the structure. In these cases, it always took 
several seconds from the moment when the microtetrapod hit a wall until complete release 
of the contained sperm, which we found beneficial to release the sperm specifically when the 
sperm reaches the intended target and hits it for a while. Sperm release occurred in both 
cases when two arms hit a corner or when four arms hit a wall, while the release processes 
were different. When the motors came into contact with the targeted barriers, they still 
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rotated for a while after the forward swimming was stopped. As shown in Figure 4.5c, the 
sperm-tetrapod rotation stopped faster when two arms hit a corner because of the geometric 
gap between the arms which was easily caught on a corner. Once the rotation stopped, the 
sperm cell escaped when the microtetrapod arms opened (release in around 7 s). When four 
arms hit a wall, the rotation was not stopped because the arms were not locked. Thus, the 
sperm release took longer when four arms were bent on a wall (around 12 s). In both cases, 
tetrapods were pushed back by around 3 µm after the sperm escaped. The reason for this 
recoil is the microtetrapod arm’s elasticity that makes them recover their original shape once 
the pushing sperm is gone and thus generate a spring force opposite to the initial pushing 
direction. Even though there is a substantial diversity in bovine sperm dimensions, 
swimming behaviors and fabricated tetrapods within a sample, more than 2/3 (15 out of 22) 
of the coupled motors were shown to have successfully released sperm cells.  
 
 
Figure 4.5. Track (red line) of a sperm-hybrid motor under magnetic guidance in the (a) 
horizontal plane and (b) vertical plane. (c) Image sequence of a sperm release process when 
the arms hit the corner of a PDMS wall. Blue arrows point at the sperm head. Time lapse in 
min:s. 
 
The mechanically triggered release performance relies on the elasticity of the microtetrapod 
arms and the sperm force. It has been demonstrated that the type of monomer and the cross-
linking parameters contribute to the elasticity of photosensitive polymeric materials.14 Thus, 
a b c 
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in order to avoid accidental release events, we did not choose a softer polymer material but 
optimized the laser power that initialized cross-linking instead. In our simulation, the 
applied force was given according to the maximum pushing force of a sperm in low-viscosity 
fluid (2.29 ·10-3 Pa·s).115 In addition, the sperm can generate a more powerful force when the 
head is pushing against an obstacle, as has been reported elsewhere.116 Moreover, the sperm 
force can be up to 20 times higher when the sperm is hyperactivated and swims in the 
viscoelastic fluid of the female reproductive system.66 All these parameters should be 
considered for future applications in vivo. 
 Cancer treatment 
4.4.1. Antitumor efficacy of drug loaded sperm.  
HeLa cells, as derived from cervical cancer cells, were cultured into spheroids as 3D tumor 
model to evaluate the influence of drug-loaded sperm on cell death (see details in Section 
3.4).92 In order to visualize the drug distribution into the tumor spheroid with no damage on 
it, we first employed FITC-BSA as a proof of concept for protein-based drugs (Figure 4.6). 
We observed that after 24 hours co-incubation of BSA-loaded sperm with spheroids, sperm 
were found not only in the solution, but also in the spheroids as shown in the overlaid z-stack 
images, demonstrating the tissue penetration capability of sperm. According to a semi-
quantitative analysis by using ImageJ, the integrated fluorescence intensity which represents 
the total amount of BSA, increased 1.8 times compared to the amount at the beginning of the 
experiment. The observed spreading area of FITC-BSA increased 7.4 times. This indicates 
that the increase of the fluorescent area was not only because more sperm swam into the 
spheroid over time, but also because more FITC-BSA was transferred from sperm into the 
HeLa spheroid. Here no further studies were performed, as in this work we focused on the 
study of the antitumor efficacy of DOX-HCl loaded sperm.  
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Figure 4.6. FITC-BSA distribution in a HeLa spheroid after the co-incubation of FITC-BSA 
loaded sperm with a HeLa spheroid. (a) Overlaid z-stack images. Red lines circle the spheroid. 
FITC-BSA is fluorescing in green under an excitation light of 470 nm. (b) Semi-quantitative 
analysis of the fluorescence intensity of the spheroid shown in (a). Area of BSA distribution 
describes the spreading area of FITC-BSA fluorescence signals on the spheroid, i.e. drug 
distribution. Integrated intensity describes the sum of fluorescence intensity in the red-
circled spheroid in (a), which corresponds to the total amount of FITC-BSA in the spheroid. 
 
The cell-killing efficacy of DOX-HCl was investigated by co-incubation of DOX-HCl-loaded 
sperm (8×104 sperm in 100 µL SP-TALP) with HeLa spheroids. Spheroids without any 
sperm or drug, with unloaded sperm and with DOX-HCl solution were cultured as control 
experiments. As mentioned above, 8×104 sperm in 100 µL solution can load at the 
maximum 1.5 µg of DOX-HCl. Therefore, the control group using DOX-HCl solution was 
prepared with the same drug concentration (1.5 µg DOX-HCl in 100 µL SP-TALP). Figure 
4.7 illustrates the drug transport into a spheroid during 72 h when it was treated with DOX-
HCl-loaded sperm. Red fluorescence shows the average intensity of 36 overlaid z-stack 
a b 
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images and indicates the presence of DOX-HCl. Gradually, DOX-HCl was found increasingly 
in the center of the spheroid over time. After 72 h, the size of all spheroids decreased due 
to the drug-induced cell death. Consequently, broken clusters and ruptured cells were 
observed in the medium (Figure 4.7 at 72 h).  
 
  
Figure 4.7. Overlaid z-stack images of HeLa spheroids under treatment by DOX-HCl-loaded 
sperm. Red color shows the fluorescence of DOX-HCl under an excitation light with a 
wavelength of 470 nm. Blue arrows point at ruptured spheroids. 
 
Figure 4.8 shows the cell viability analysis performed by LIVE/DEAD staining with SYBR 
Green Kit.117 In the first 24 h of culture there was no significant change in all groups while 
after 48 h DOX-HCl-loaded sperm showed a cell-killing effect comparable to the DOX-HCl 
solution treatment with the same amount of DOX-HCl. A lower percentage of live cells was 
found after the treatment with DOX-HCl-loaded sperm (47%) or DOX-HCl solution (45%) 
compared to the spheroid control group (68%). After 72 h, no significant decrease of cell 
viability was found in the samples of control spheroid and DOX-HCl solution. In contrast, 
the sample with DOX-HCl-loaded sperm showed the lowest percentage of live cells (13%) 
among all groups. Unloaded sperm showed a negative effect on HeLa spheroids as well, as 
the percentage of live cells was only 37%, probably attributed to the spheroid 
disintegration induced by the sperm beating and hyaluronidases reaction (from sperm 
membrane) with the extracellular matrix. Hyaluronidases are enzymes expressed by sperm 
to catalyze the degradation of hyaluronic acid, the extracellular matrix of oocyte-
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surrounding cumulus cells.118 However, it is also well-known that hyaluronic acid plays an 
important role in the proliferation and migration of tumor tissue.92 Therefore the motility 
and the hyaluronidases wielded by sperm cells allow them to penetrate deep into a tumor 
spheroid not only to disintegrate it but also to achieve an effective in situ drug 
administration. 
 
Figure 4.8. (a) Histogram of the percentage of live cells relative to the total amount of cells 
at different time points. (n = 4, cell count = 104 for each sample, * p < 0.01, ANOVA analysis, 
degree of freedom for T-test is 6). (b) LIVE/DEAD staining images of cells from digested 
spheroids at 72 h.  
 
In our experiment, HeLa spheroids were cultured for 3 days in advance. During cell culture 
in the lab, HeLa spheroids sustain a balance between cell proliferation and death.117 When 
the number of live cells increases, the number of dead cells increases as well, especially in 
the necrotic core of the spheroid, as the nutrients from the medium can hardly reach the 
a 
b 
 52 
 
interior cells. Since DOX-HCl in solution phase can be rapidly taken in by the outer cell layer 
of spheroids, a pronounced effect of the DOX-HCl solution group in the first 48 h was 
observed. However, when dissipated in the cell medium, diluted DOX-HCl was apparently 
not sufficient to induce the death of more cells from 48 h to 72 h (Figure 4.8b). This 
manifests an advantage of the sperm-hybrid delivery system for the in vivo application 
scenario: the ability to avoid drug dilution in body fluids. Overall, by means of functional 
combination of cargo protection and tissue penetration of sperm and the cell-killing efficacy 
of the drug, this biocompatible delivery strategy employing DOX-HCl-loaded sperm cells 
poses an intriguing alternative dosage form that is able to induce a death rate of nearly 90% 
after 72 h of treatment on HeLa spheroids, as it is shown in Figure 4.8.  
4.4.2. Cancer treatment by DOX-HCl loaded sperm-motors 
In vitro drug delivery experiments were performed in a microfluidic channel to investigate 
the potential application of the sperm-hybrid micromotors for drug delivery (Figure 4.9a). 
As depicted in Figure 4.9b, sperm are first loaded with DOX-HCl, then coupled in 
microtetrapods. After essential guidance, the DOX-HCl loaded tetrapod-like sperm-motors 
reach the target and then discharge the drug loaded sperm.  
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Figure 4.9. (a) Schematic of the microfluidic chip for drug-loaded sperm transport and 
delivery. (b) Schematic depicting tumor targeted drug delivery by a sperm-hybrid 
micromotor under magnetic guidance with mechanical sperm release trigger. 
 
In order to observe the sperm release in details, sperm-hybrid micromotors were first 
guided to HeLa cell clusters by using external magnetic fields. Figure 4.10a shows an 
example of how a coupled sperm cell was released on a cells cluster, and adhered to one of 
its cells. The same sperm release mechanism was observed with DOX-HCl-loaded sperm- 
hybrid micromotors that targeted dense HeLa spheroids. We successfully achieved the 
transport of a DOX-HCl-loaded sperm cell through a microfluidic constriction channel and its 
release into a tumor spheroid. The distance travelled in this experiment was ca. 1.8 cm in 
total and the journey took approximately 8 minutes. The sperm cell was released as the 
microtetrapod arms hit the outer boundary of the tumor spheroid, and then continued 
swimming through it until it adhered to one of the cells. Figure 4.10b shows the release 
distribution of delivered DOX-HCl over 8 hours. The measured fluorescence intensity of the 
drug-loaded sperm decreased while the fluorescence signal spread over the spheroid over 
time. This indicates that DOX-HCl was released from the sperm cell into the spheroid. After 
8 hours, the targeted HeLa cell experienced a significant cell body shrinkage (size decreased 
by about 40%), which is known to be a sign of the first stage of cell apoptosis.119   
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Figure 4.10. (a) Image sequence of the sperm release process when the arms hit HeLa cells. 
Time lapse in min:s. Red arrows point at the sperm head. (b) DOX-HCl distribution in a HeLa 
spheroid with overlaid z-stack images of the fluorescence channel (20 images with a stack 
separation distance of 2 µm). Red arrows point at the sperm head. 
 
Figure 4.11 shows scanning electron microscopy images of the membrane fusion of sperm 
and HeLa cells. A HeLa spheroid that was treated with unloaded sperm served as a control 
sample in this experiment. 24 hours after the sperm release event, the anterior part of the 
sperm head was fused with the targeted HeLa cell while the midpiece and the flagellum 
remained outside. Blebs and vesicles were observed on the HeLa cell that was fused with a 
DOX-HCl-loaded sperm, indicating its death by apoptosis (Figure 4.11a). Cells fused with 
unloaded sperm did not show such blebs (Figure 4.11b) and thus were presumably still 
alive, just as unfused cells. In literature, this interaction between sperm cells and somatic 
cells is attributed to the somatic fusion ability of acrosome-reacted spermatozoa.78 So, by 
taking advantage of this sperm cell fusion ability, the direct transfer of the drug from sperm 
to cancer cells minimizes the dilution of drug into extracellular matrix or body fluids. At the 
current stage, the dosage that one single delivered sperm carried, and the resultant drug 
a 
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distribution that could be observed nearby after tumor infiltration, was apparently not 
sufficient to induce the cell death of the whole spheroid. This makes the investigation of 
multi-sperm transport necessary, which will be pursued in future studies to achieve an 
effective tumor treatment. 
 
 
Figure 4.11. SEM images showing the sperm-HeLa cell fusion. (a) Cell fusion with the DOX-
HCl-loaded sperm; (b) Cell fusion with an unloaded sperm. Red arrows point at a cell in 
apoptosis and the blue arrows point at live cells. 
 
 Summary 
In summary, a drug delivery system based on sperm-hybrid micromotors was proposed. In 
such an assembly, sperm are utilized as drug carriers for potential cancer treatment in the 
female reproductive tract, as the sperm can swim into a tumor spheroid thanks to its capacity 
to fuse with somatic cells, transferring the drug efficiently to the target cell/model tumor in 
the process. sperm also showed a high drug encapsulation capacity of ca. 15 pg per sperm. 
Moreover, the sperm cell serves as propulsion source while a magnetic microstructure is 
used for guidance and release of the sperm: When the arms of the microstructure hit HeLa 
cells, they bend and thus open a way to free the sperm. Bovine sperm were used as model 
cells to load DOX-HCl as a model drug against HeLa cells. For that, HeLa cell spheroids were 
cultured as an in vitro tumor model. DOX-HCl was locally distributed into the HeLa cell 
a b 
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spheroids, showing higher tumor cell-killing efficacy (87 %) within the first 72h, compared 
to simple drug solution (55%) with the same dose.  
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5. Human sperm as a medication for early ovarian cancer 
This chapter is based on the publication of arXiv preprint, 2019, 
https://arxiv.org/abs/1904.12684, titled: Human Spermbots for Cancer-Relevant Drug 
Delivery. 
 Background 
Ovarian cancer ranks fifth amongst cancer deaths in women, and top amidst all gynecological 
cancers. Less than 30 percent of women survive the disease for more than ten years.120 
Fallopian tubes are found to be the main primary lesion of ovarian cancer, especially high-
grade serous ovarian cancer (HGSOC), the most common and aggressive type of ovarian 
cancer.121 However, fallopian tubes are narrow structures situated deep inside the body, and 
thus, notoriously difficult to access, making it challenging to examine or eliminate them in a 
non-invasive manner. Most current anti-cancer treatments rely on generic chemotherapies 
and can lead to severe side effects, such as nausea, fatigue, anemia and infection.122 Drug 
delivery of chemotherapeutics is usually mediated by passive carriers that rely on the body’s 
circulatory system, and thus, pose significant challenges regarding their applicability for 
long-distance transport and targeting.123 Therefore, new technologies that can access 
fallopian tubes to treat such cancer precursor lesions are sorely required.  
Sperm-motors are excellent candidates not only to perform their natural function of 
fertilization but also to target gynecological cancers, in particular early pre-invasive HGSOC 
lesions, also known as serous tubal intraepithelial carcinoma (STIC) lesions, as an early non-
invasive treatment option. Chapter 4 presents the anti-cancer potential of bovine sperm. 
Given the ultimate goal of translating sperm-based drug delivery to human patients and 
considering potential acceptance issues surrounding bovine sperm, success of the next steps 
of this technology critically depends on the transferability to human material. This challenge 
represents no minor obstacles given the major differences in the makeup between animal 
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and human sperm. Thus, besides anatomical differences, sperm obtained from different 
species can vary in their membrane composition, which could impact on the drug 
translocation process.124 Moreover, bovine sperm DNA is condensed via a single packaging 
protein known as protamine P1, whereas human sperm make use of two different 
protamines, P1 and P2, with also some residual histone packaging, leading to highly diverse 
chromatin structures and increased stability of chromatin in bovine over human sperm.125 
In addition, human sperm nuclei are more variable than those of many other species.126 Thus, 
it is not surprising that translatability of results from bovine to human sperm is deemed 
challenging. Moreover, the efficacy of bovine spermbots has only been previously tested on 
overpassaged cervical cancer cells, in which decades of genetic and phenotypic drift have led 
to major differences between cell line batches as well as to the original cancer.127 Therefore, 
the efficacy of engineered human sperm in more patient-representative cancer models of the 
reproductive tract are highly desired. As the reproductive cancer of strongest unmet need 
and due to its unique etiology inside the fallopian tube, ovarian cancer, particularly HGSOC, 
is especially attractive in this regard.  
In chapter 4, we presented a tetrapod-like microstructure for the transport of drug-loaded 
bovine sperm and confirmed the cancer-killing effect of this targeting drug delivery system. 
However, the drug-loading properties of human sperm and their successful implementation 
into a steerable micromotor remain unstudied. Here, we present a fully functional drug 
carrier based on human sperm. We shed light on the subcellular localization of a 
chemotherapeutic drug inside the sperm, investigate the interaction between the drug and 
human sperm and measure the anticancer efficacy of this system for the first time on 3D 
reproductive cancer cell cultures including early-passage ovarian cancer HGSOC patient 
samples (Figure 5.1). Moreover, we establish a new streamlined cap to transport and 
release human sperm. These streamlined sperm-motors start addressing major challenges 
towards the in vivo application of the technology, such as efficient targeting of cancer tissues 
via external magnetic guidance and drug-dose control through simultaneously supplying 
defined numbers of human sperm loaded with known concentrations of chemotherapeutic 
drugs.  
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Figure 5.1. Human sperm-based drug-delivery system to target early ovarian cancer 
precursor lesions. Inset shows an alternative design for carrying human drug-loaded sperm. 
 
 DOX-HCl loading in human sperm 
DOX-HCl was loaded into human sperm as introduced in Section 3.3. The loading ratio was 
determined by fluorescence spectrometry by a direct method, different from the 
measurement for bovine sperm. After 1 h of co-incubation, 3.32 ± 1.4% of DOX-HCl (50 
µg/mL) was loaded into 3 × 105 sperm. The drug loading in one sperm is 5.53 ± 2.34 pg. 
Compared to the research on bovine sperm in chapter 4, in which the encapsulation capacity 
of individual bovine sperm was determined at around 5.53 pg, human sperm show a lower 
encapsulation capacity in line with their smaller size (around 1/8 the volume of bovine 
sperm). Figure 5.2a exhibits a cluster of human sperm loaded with DOX-HCl, as indicated by 
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their red fluorescence at an excitation wavelength of 458 nm (DOX-HCl autofluorescence). 
According to our observations by fluorescence microscopy, DOX-HCl was successfully loaded 
not only into motile but also into immotile sperm cells. In fact, we observed almost complete 
penetrance of drug loading in sperm obtained from a total of 22 patients and donors sampled 
in this study. 
Using confocal laser scanning microscopy combined with an Airyscan system for high- and 
super-resolution sperm imaging, we obtained in-depth information on the intracellular 
location of the encapsulated drug inside human sperm. We first fixed the drug-loaded sperm 
with paraformaldehyde to preserve their internal structure. Outer sperm membrane was 
stained with Alexa Fluor 488-conjugated wheat germ agglutinin (WGA), a lectin selectively 
binding to N-acetylglucosamine and N-acetylneuraminic acid residues of glycoproteins 
present in the sperm membrane and detectable at an excitation wavelength of 514 nm.128 
Likewise, DOX-HCl was detected using an excitation wavelength of 458 nm. Acquired z-stack 
images, separated by 10 nm, showed clearly the drug distribution in different planes. As 
shown in Figure 5.2b, DOX-HCl was detectable predominantly in the sperm head. Notably, 
98% of the sperm head is occupied by the nucleus after maturation.129 Based on this fact, we 
conclude that DOX-HCl localizes to the sperm nucleus, in agreement with the high DNA-
affinity exhibited by DOX, which might enable DOX-HCl binding to chromosomal sperm 
DNA.108 We also observed structures resembling nuclear vacuoles130 in the drug-loaded 
sperm (Figure 5.2c), where little or no DOX-HCl could be detected. The location of these 
structures differed among individual sperm. In addition to the advantages of DOX-HCl as a 
therapeutic molecule, it also has potential to be used as a dye to further characterize sperm 
nuclei in living and motile sperm cells in the future. We further confirmed that WGA can 
serve as an efficient membrane dye for human sperm, clearly depicting the structure of the 
sperm membrane around the head, midpiece and tail regions. Particularly, there was a 
staining difference between the peri-acrosomal space and the post-acrosomal region, which 
in the future could be helpful to gain insights into different subcellular compositions of 
sperm membranes. Based on the 3D-reconstructed image of the DOX-HCl loaded sperm in 
Figure 5.2b, the volume of the sperm was integrated to be 14.2 µm3. Thus, the DOX-HCl 
density was calculated to around 0.38 g/mL as the ratio of the above-mentioned amount of 
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drug loaded per sperm to its volume. Since the nucleus of a single sperm contains around 
3.23 × 1010 nucleotides,131 we deduce that around 1.70 × 10-23 g of DOX-HCl would be 
available for binding per base pair, meaning that a single DOX-HCl molecule could bind to 
roughly every 6th nucleotide of the DNA. 
Moreover, the percentage of motile sperm was preserved after drug loading, similarly to our 
previous work performed on bull sperm. Statistically, the average velocity of human sperm 
after 1 h of drug loading (18 ± 5 µm/s) showed no significant difference to unloaded sperm 
(21 ± 5 µm/s) according to measurements using a computer-assisted sperm analysis 
software package (CASA auto-tracking system). Since the properties of sperm samples from 
different patients and donors markedly differ, we compared the same sperm sample before 
and after drug loading. The above-mentioned drug loading process was performed at room 
temperature to optimize sperm motility and viability for extended periods of time (about 24 
h). We also studied sperm motility at 37°C as the physiological temperature at which human 
sperm operate in vivo. In this experiment, an unloaded sperm sample served as a control, 
which was incubated in sperm medium (SP-TALP) under the same incubation and 
purification conditions as the drug-loaded sperm but in the absence of DOX-HCl. Motilities 
of both sperm samples decreased similarly over time: after 8 h of incubation, around 10% of 
sperm remained motile in both groups (Figure 5.2d).  
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Figure 5.2. DOX-HCl loading sperm. (a) Merged fluorescence and bright-field images of DOX-
HCl-loaded sperm. Red color indicates autofluorescence of DOX-HCl. (b) Fluorescence and 
Airyscan images of two DOX-HCl-loaded human sperm, revealing the precise location of 
DOX-HCl inside sperm heads. Green indicates membrane staining by Alexa Fluor 488-
conjugated wheat germ agglutinin (WGA). Red indicates DOX-HCl autofluorescence within 
sperm heads. (c) DOX-HCl localizes to the nucleus inside the sperm head. Detailed 
information on three different sperm cells. White arrows point at structures resembling 
nuclear vacuoles. DOX-HCl autofluorescence shown in red; Alexa Fluor 488-conjugated 
wheat germ agglutinin shown in green. (d) Percentage of motile sperm monitored over 8 h 
in unloaded and DOX-HCl-loaded human sperm (data represent means of two different 
samples, with a sperm count of 100 sperm per sample. Error bars represent standard 
deviations between samples). 
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 Anticancer effect 
We evaluated the anticancer effect of DOX-HCl-loaded human sperm by performing 
cytotoxicity assays of relevant cancer cell spheroids. Firstly, we tested the influence of sperm 
medium (SP-TALP) on 3D cell cultures of cervical cancer-derived HeLa cells. After 96 h of co-
incubation, we detected 148,406 ± 5,531 living cells after treatment with SP-TALP (100 µL 
SP-TALP in 4 mL cell solution), showing no significant difference to the cell number in the 
untreated control group (151,250 ± 1,750 cells). Since the sperm medium had no significant 
influence on cell proliferation, any cell number variations in the subsequent experiments can 
be attributed to the anti-cancer effects of human sperm and/or the chemotherapeutic drugs 
they carried. Chapter 4 presented the killing effect of drug-loaded bovine sperm on HeLa 
cells spheroids. To test if drug-loaded human sperm were also able to induce cytotoxicity in 
HeLa cell spheroids, we plated equal amounts of HeLa cells (2 × 105 cells resuspended in 4 
mL cell medium) onto 16 3.5-cm cell-repellent dishes and incubated them for 2 days to 
induce spheroid formation. The resulting spheroids were split into 4 groups and co-
incubated separately with the following samples: (i) DOX-HCl-loaded and (ii) unloaded 
human sperm (104 sperm for each sample, suspended in 100 µL SP-TALP), (iii) 53 ng DOX-
HCl dissolved in 100 µL SP-TALP, equaling the amount of DOX-HCl added in (i), and (iv) a 
blank control using 100 µL of HeLa cell medium. DOX-HCl-loaded sperm were purified to 
remove the excess of drug after the loading process, prior to treatment. After 96 h of 
treatment with DOX-HCl solution HeLa spheroids showed no difference compared to the 
blank control and remained intact displaying smooth and distinct outer spheroid boundaries. 
By contrast, spheroids treated with DOX-HCl-loaded sperm became severely disintegrated 
leading to a plethora of small cell aggregations, floating cells and ruptured cell fragments 
(Figure 5.3a), while unloaded human sperm elicited intermediate effects. Conceptually, 
metastatic cancer progression relies on individual, or clusters of, cancer cells dissociating 
from the original tumor, traveling to their secondary sites, and reattaching there.132,133 To 
mimic aspects of this process in vitro, we briefly trypsinized the spheroids after 96 h in all 
groups to obtain single-cell suspensions that we re-seeded into 10-cm cell culture dishes. 
After 12 h of attachment inside the incubator, we estimated the cell re-attachment capability 
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as the ratio of attached cells in the group-of-interest to that of the control group. As 
demonstrated in Figure 5.3b, treatment with DOX-HCl-loaded human sperm led to 
drastically reduced re-attachment rates of HeLa cells, as illustrated by an elimination of 93.8% 
of the cells compared to the control. Unloaded human sperm also impacted on HeLa 
spheroids, leading to a reduction in re-attachment to 58.0%. This sperm-specific effect that 
was independent of DOX-HCl could be due to partial spheroid disintegration and cell damage 
induced by the sperm’ hyaluronidase reaction and tail beating, an intriguing aspect of this 
micromotor system that requires further investigation in the future. It was reported before 
that the plasma membrane and DNA of cancer cells can be damaged by external mechanical 
beating produced by rotating microdiscs.134 Our findings suggest a new route for 
mechanically induced cancer cell death by sperm tail beating. Compared to the microdisk 
beating, sperm possess a more powerful motorized structure, with their tail beating capable 
of generating forces up to 450 pN.66 Cell integrity can be damaged under such a hitting force. 
In the drug solution group, which contained the same overall DOX-HCl amount as the drug-
loaded sperm, DOX-HCl was present at a final concentration of 13.25 ng/mL in the cell 
medium, lower than the effective dose that HeLa cells are sensitive to.135 Consequently, no 
effective impact of cell re-attachment was observed in this group, in agreement with our 
previous results using bull sperm. 
 
 
Figure 5.3.  Anti-cancer effects of DOX-HCl loaded human sperm on Hela cells. (a) 
Optical microscopy images of HeLa cell spheroids before and after 96 h of treatment with 
drug-loaded human sperm. (b) Survival rate of HeLa spheroid-derived cells after 96 h of 
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treatment (data represent means +/- standard deviations of n = 4 independent biological 
replicates, HeLa cell count ~1.5 × 105 in blank spheroids. * p < 0.01, ANOVA analysis). 
 
HeLa cells were established in the 1950s as the first in vitro cancer model system and 
immortalised cancer cell line. While major breakthroughs have been and are being 
accomplished using this cell line, the thousands of passages that HeLa cells have undergone 
since its establishment have led to the acquisition of many de novo characteristics that vary 
between different HeLa batches and their cervical cancer of origin.136 Therefore HeLa cells 
and other common overpassaged cancer cell lines are limited in predicting the cellular and 
molecular behaviors of cancers and patient responses in vivo, such as drug resistance 
mechanisms.137 To obtain a better understanding of the reaction of appropriate original 
tumor cells to DOX-HCl-loaded sperm, we assessed the anti-cancer effects on ex-vivo 3D 
cultures of early-passage ovarian cancer samples derived from an HGSOC patient (OCMI66). 
The OCMI66 cells are part of a living ovarian cancer cell biobank recently generated and 
characterized by one of our teams at the Manchester Cancer Research Centre (Nelson et al., 
has been submitted). The samples in this biobank were extensively validated by p53 
profiling, exome sequencing, global transcriptomics and karyotyping based on single-cell 
whole genome sequencing. Moreover, these cells have been cultured in vitro for only short 
time periods, minimizing the risk of genetic and phenotypic drift phenomena that could 
potentially mask key molecular features of the original tumour. Indeed, drug profiling of 
these cancer samples demonstrated that their sensitivities are consistent with patient 
responses, highlighting the potential of these biobank cultures as an invaluable tool for 
making in vitro discoveries with improved translational potential over conventional cancer 
cell lines. 
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Figure 5.4.  Anti-cancer effects of DOX-HCl loaded human sperm on HGSOC cells. (a) 
Optical microscopy images of HGSOC cell spheroids before and after 96 h of treatment with 
drug-loaded human sperm. (b) Survival rate of HGSOC spheroid-derived cells after 96 h of 
treatment (data represent means +/- standard deviations of n = 4 independent biological 
replicates, HeLa cell count ~1.5 × 105 in blank spheroids. * p < 0.01, ANOVA analysis). 
 
Ovarian cancer is of particular interest to the spermbot technology presented in this work, 
as it represents the highest unmet need of all gynecological cancers.120 Moreover, while it 
was long assumed that the majority of ovarian cancers originate from within the ovaries, it 
is now well established that the most aggressive and common type of ovarian cancer, HGSOC, 
develops as STIC lesions inside the fallopian tube, an area of the reproductive tract currently 
impossible to access for molecular analysis with non-invasive technologies.138 This recent 
dogma change in ovarian cancer etiology makes sperm-based drug delivery to pre-invasive 
HGSOC lesions a highly desirable and timely approach. 
The spheroids that OCMI66-derived HGSOC cells formed were looser and smaller compared 
to HeLa spheroids, possibly because of the high migration activity we observed in these cells 
when grown on 2D cell culture dishes (Figure 5.4a). Similar to sperm treatment of HeLa 
cells, DOX-HCl-loaded human sperm showed a high reduction of re-attachment of OCMI66-
derived cells of up to 93.3%, while DOX-HCl solution barely influenced the re-attachment 
rates of OCMI66-derived cells. Surprisingly, unloaded human sperm also showed a strongly 
reduced re-attachment of 79.4% in these experiments (Figure 5.4b). A potential reason 
could be the looser structure of OCMI66-derived spheroids over those of HeLa cells, making 
a b 
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them more susceptible to sperm-mediated disintegration and cell death through tail beating. 
These tests demonstrate a high effectiveness of drug-loaded human sperm on early-passage 
HGSOC cancer samples and have potential to lay the groundwork for new routes of 
biocompatible and non-invasive cancer treatments in humans in the future. 
DOX-HCl-loaded sperm represent a new approach with great potential for effective cancer 
treatment of gynecological cancers of unmet need. The approach combines advantages of 
chemical medication with biological properties of sperm (active motion, somatic cell fusion78 
and mechanical tail beating). Sperm-mediated drug delivery holds promise for drug dosing, 
encapsulation and transport. Specifically, membrane encapsulation can protect functional 
drugs (DOX-HCl) from dilution by body fluids and enzymatic degradation. Moreover, the 
presence of chromosomes in the sperm head has potential to provide ample opportunities 
for intracellular storage of DNA-binding drugs such as DOX-HCl. In addition, the ability to 
self-propel combined with peristalsis of female reproductive organs make sperm attractive 
for carrying drugs for long durations and distances inside the gynecological tract in a 
protected manner. Since this is the first exploration of human sperm as a therapy for 
gynecological cancers, the complete mechanism of drug transfer remains unclear. However, 
it is intriguing to speculate that the ability of sperm to fuse with somatic cells as previously 
reported has potential to enhance the drug uptake by cell-to-cell transfer.[14,24] In this regard, 
it is notable that sperm are capable to fuse with a variety of cells and that the resulting 
chimeric cells can be stably cultured for more than 50 passages.80 As a consequence, local 
transfer of entrapped drugs to targeted cancer cells via sperm-cell fusion and/or alternative 
mechanisms could increase the utilization ratio of the loaded drugs, which could improve 
drug efficacy and potentially reduce the development of drug resistance.139 
 
 Streamlined sperm-motor transport toward tumor spheroid  
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Although randomly propelling DOX-HCl-loaded human sperm show an encouraging 
therapeutic effect on the cancer cells tested in this study, being able to target the drug-loaded 
sperm to the cancer spheroids would facilitate more efficient dosage and reduce undesired 
drug accumulation. Towards this aim, a streamlined cap was designed as a hollow semi-
ellipsoid structure for human sperm transport. The contact surface in an ellipsoid shape can 
largely avoid turbulence flow, thereby decreasing the pressure drag on the structure. As 
illustrated in Figure 5.5a, the water resistance and energy loss of this streamlined cap were 
reduced to one third of that of a tubular cap based on the same diameter and length. With a 
lower flow resistance, such a sperm-hybrid micromotor saves energy and is thus expected 
to swim for longer time periods. These microcaps were fabricated by FSTL and coated with 
Fe so that they can be aligned by external magnetic fields (for details, see 3.2). Owing to 
protective coating with Ti, the microcaps had no negative impact on cell growth compared 
to the blank control group (Figure 5.5b,c), consistent with Ti being considered as a 
biocompatible material140.  
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Figure 5.5. (a) Flow simulations of (i) a streamlined and (ii) a tubular sperm cap based on 
the same diameter and height. Red arrows indicate the swimming direction of the microcaps. 
Blue arrows point at the fluid flow. Finite element analysis tool: SOLIDWORKS Flow 
Simulation; flow medium: water; velocity: 21 µm/s (the average velocity of a spermbot at 
20℃ in HeLa medium); roughness: 0; f: total resistance. Biocompatibility evaluation of the 
microcaps. (b) Optical images of (i) microcaps treated group and (ii) cell medium control 
group. Scale bars: 30 µm. (c) HeLa cell survival after 3 days culture. 
 
The sperm were mechanically coupled by co-incubating them with the caps (Figure 5.6a). 
The large opening at the equatorial plane of the cap enabled us to couple up to 3 human 
sperm in a single cap at the same time (Figure 5.6b), showing a new way for multiple sperm 
transport (Figure 5.6c). Apart from the difference in shape from the previous tetrapod-
motor, the new cap designs were much larger in relative size ratio. Specifically, the opening 
diameter was ~6 times as big as the width of human sperm heads for the new cap compared 
to a 4:1 ratio for the previously reported tetrapod-motor.[14] The feasibility of generating 
functional sperm-based micromotors in this size range represents a critical step towards 
future real-time in vivo imaging of spermbots inside the reproductive system in preclinical 
experiments.34 As such, these hybrid micromotor designs provide an important starting 
point to facilitate real-time guidance of sperm to their desired destinations within the 
reproductive tract.  
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Figure 5.6. (a) Drug-loaded spermbot approaching OCMI66 cell spheroid. (b) Transport of 
up to three human sperm using the proposed streamlined magnetic cap. (c) Magnetic 
guidance of a human spermbot. 
Moreover, here we developed a simple sperm release mechanism by swerving the cap via 
rapid change of orientation of the imposed magnetic field (Figure 5.7a). This technique has 
been applied before to release individual cells or particles hydrodynamically from an 
artificial support structure.141 Figure 5.7b shows the complete process to transport and 
release sperm onto a cancer cell spheroid. The sperm was coupled to a streamlined microcap 
and guided to an OCMI66-derived HGSOC cell spheroid. Then, we rotated the external 
magnet to turn over the microcap thereby releasing the sperm. The contact surface of the 
sperm and the cap are assumed to be smooth without causing friction in between the two 
surfaces. As a result, the theoretical swerve angle for decoupling is 90°. Whereas the sperm 
head undergoes a wiggling angle (57°) on the short-time scale to balance the torque 
generated by tail beating, the resulting theoretical swerve angle was deduced to be 147° to 
ensure a successful release. The larger the swerve angle, the higher the swimming stability 
of this system but the more difficult it is to release the sperm. Hence, this approach relies on 
a compromise between swimming stability and release reliability to ensure optimal 
microcap function. After the sperm escaped the cap, it swam towards the cancer cell spheroid 
tissue. In the future, further experiments need to be implemented to evaluate the efficiency 
of this release mechanism for cancer treatment. 
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Figure 5.7. (a) Ejection mechanism of sperm from streamlined cap. The sperm head was 
regarded as an ellipse in its projective plane, in which the projection of the streamlined cap 
takes the shape of a semi-ellipsoid structure (blue line). The encapsulated sperm bears a 
drag force along its long axis (i) and can only move tangentially in the semi-ellipsoid 
structure of the cap.  The cap swerving is carried out by rapidly changing the direction of the 
imposed magnetic field. In this situation the torque is always directed along the tangent line 
in the same direction of the drag force during continuous swerving of the cap (ii). Sperm 
escape occurs when the drag force becomes perpendicular to the tangent line (iii). After 
taking the wiggling angle of the sperm head (θ, 57°, middle panel) into account, the resultant 
critical decoupling angle is shown as φ (147°). (b) Guidance and release of a DOX-HCl-loaded 
human sperm onto an OCMI66 cell spheroid. 
 
 Summary 
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This chapter presents the application of human sperm combined with DOX-HCl for potential 
treatment of female gynecologic diseases, in particular cervical and ovarian cancers of unmet 
need. Human sperm can encapsulate DOX-HCl in their crystalline nuclei,72 where we 
observed its presence using high- and super-resolution laser microscopy. Moreover, due to 
the compact membranes of sperm,142 hydrophilic drugs taken up and encapsulated by the 
sperm are well protected from dilution by body fluids and enzymatic degradation. We 
calculated that each DOX-HCl loaded sperm can hold around 5.53 pg of drug, indicating a 
potential binding ratio of around 1:6 DOX-HCl molecules to nucleotides. Neither the viability 
nor swimming performance of human sperm was markedly affected by drug loading, 
indicating the robustness and potential suitability of this protocol for future treatments 
using human sperm as drug carriers. These findings are likely to significantly broaden this 
research field not only regarding sperm as drug carriers, but also for using DOX-HCl as an 
alternative non-invasive nuclear dye to further observe and characterize nuclear structures 
inside living sperm. Re-attachment tests demonstrated strong anti-cancer effects of drug-
loaded human sperm on spheroids derived from a commonly used cervical cancer cell line 
and HGSOC cells recently extracted from an ovarian cancer patient. The latter cells are part 
of a newly established ovarian cancer biobank, known to display key features of the original 
cancer such as the responsiveness to certain chemotherapeutic drugs. Over 94% of cancer 
cells were incapable of re-attaching after 4 days of treatment in both cases. Combined with 
the proposed streamlined microcaps, drug-loaded human sperm can be precisely guided to the 
specific cancer target in vitro. 
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6. Sperm-motors for cargo delivery through flowing 
blood 
This chapter is based on the publication titled: Sperm Micromotors for Cargo Delivery 
through Flowing Blood. Reprinted with permission from [ACS nano, 2020, 14(3), 2982-2993] 
(doi.org/10.1021/acsnano.9b07851). Copyright [2020] American Chemical Society. 
 
 Background 
While micromotors are attracting intensive attention in the exploration of the next 
generation of drug delivery systems, the blood circulation system, as the most common 
administration route, has only rarely been explored as a transportation route for 
micromotors. Among the few attempts, catalytic microjet engines were shown to swim in 
H2O2 solutions containing ten times diluted red blood cells under static conditions.143,144 
Magnetically-driven micro-helices were also tried out in blood dilutions, observing a stick-
and-slip motion, which was related to the colloidal jamming of the blood cells.145 Another 
attempt was made by using CaCO3 microparticles as potential hemostatic agents.49 Unlike 
the first two cases where micromotors moved in static blood solutions, CaCO3 microparticles 
swam against blood flowing up to 5.9 mm/s by the propulsion of locally generated CO2 
bubbles, though with only random motion due to the lack of a guidance mechanism. However, 
the above-mentioned self-propelled particles and microengines were driven by toxic fuels 
like H2O2 or acidic substances, being far away from any application in living organisms when 
envisioning a medical treatment. Another strategy has been to turn red blood cells (RBCs) 
into micromotors. Wu et al. functionalized RBCs with magnetic particles for guidance while 
propelling them with acoustic waves. The experiments in this work were focused on 
studying the stability of RBCs micromotors under acoustic waves, but experiments under 
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flow conditions showing a specific function of cargo release were not shown.55 A more recent 
work reported a 2 mm helical robot able to perform mechanical rubbing of blood clots in in 
vitro and ex vivo models containing PBS buffer against a flow of ca. 10 mL/h, which 
corresponds to a flow velocity of 0.22 mm/s (considering a vessel diameter of 4 mm).146 The 
flow rate in this work was similar to that of small arterioles, capillaries, and venules. 
However, the operation of micromotors under more realistic blood stream conditions 
remain a challenge due to the high complexity of the blood fluid and its high flow rates in the 
circulatory system. Besides, blood contains a variety of macro- and small molecules which 
can influence the motion and function of any medical micromotor.147 Blood pH is regulated 
in a narrow range between 7.35 and 7.45, thus, any modification of the blood composition 
by adding other substances for fueling the micromotors would be lethally harmful in any 
further realistic application.148 Half of the whole blood consists of different cell types, 
including 5×109 red blood cells/mL,147 which would continuously interfere with the 
micromotors mobility, consuming a lot of energy in the process. Finally, micromotors are 
also exposed to the innate immune system in blood, which would eliminate the micromotors 
by e.g. phagocytosis when specific receptor activation is induced by the micromotors149 or 
the micromotors have too small size (<5 µm).150,151 
To overcome the abovementioned hurdles, sperm-based micromotors seem more promising 
to our view. The most important feature of sperm micromotors to operate in the blood 
stream, is in our view their ability to swim against flow (rheotaxis), which is one of the most 
efficient guidance mechanisms for sperm to reach the oocyte when accomplishing their 
natural function,152 Additionally, in combination with a synthetic magnetic scaffold, sperm-
micromotors can be precisely guided and operated by an external magnetic field to further 
release a cargo at the right place and time. It is also believed that sperm-micromotors could 
operate for longer times in the human body before being eliminated by the immune system 
due to their higher propulsion force compared to the migration speed of phagocytes,153,154 
and their size differences.151 In addition, some specific proteins expressed on the sperm 
membrane and the proteasomes can suppress the local immune reaction.155,156 It is also 
worth noting that unlike active bacteria, sperm do not proliferate or secret any harmful bio-
substances, making them safe for medical use.  
 75 
 
In this chapter, we present streamlined-horned caps (SHCs) hybrid sperm-micromotors 
(Figure 6.1), which can efficiently and controllably swim against flowing blood. We optimize 
the hydrodynamic structure of the sperm-micromotor to be able to adapt to high flow rates 
and explore its flow-resisting capability. The sperm-micromotors furthermore are 
assembled into train-like carriers (sperm-trains), allowing the guidance of multiple sperm 
and enabling multiple functional cargoes transport. As a proof-of-principle of a potential 
medical use, we functionalize the microcaps with heparin-loaded liposomes to realize a 
localized anticoagulant function. This study not only opens up new application scenarios for 
medical micromotors in the circulatory system, but envisions a new administration route of 
sperm or sperm-hybrid micromotors for future therapeutical applications. 
 
Figure 6.1. Concept of the blood-adapted SHC sperm-micromotors 
 
 Design and characterization 
Different to other in vivo applications, any medical mission in blood faces a particularly 
complicated working environment, including the presence of various substances and cells, 
complex hemorheological properties, and high flow rates. In order to efficiently design and 
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manufacture a sperm-micromotor, we first ran flow simulations and compared the 
hydrodynamic characteristics of two different designs, a tubular and a streamline-horned 
cap (SHC) with the same diameter (13 µm) and height (15 µm). Figure 6.2a shows the 
relative pressure on both cap designs when subjected to an aqueous solution containing 
solid spheres of about 5 µm diameter. As expected, the tubular cap is obstructed by the 
spheres-mimicking cells on its front surface with a high static pressure. In contrast, the shape 
of the SHC facilitates the passing of the sphere-mimicking cells forming a stable wake flow 
around it. At a swimming speed of 50 µm/s, the energy loss of the SHC is about 47% of the 
tubular cap one. To verify the performance of both designs, the microcaps were fabricated 
by two-photon lithography (SEM images of the SHC are shown in Figure 6.2b), followed by 
the coating of Fe, Ti and SiO2 nanofilms for both magnetic guidance and biocompatibility. 
 
Figure 6.2. (a) Hydrodynamic simulations of (i) tubular and (ii) SHC caps, assuming a 
swimming speed of 50 µm/s and particles mimicking red blood cells of 5 µm in diameter. 
Blue arrows point at the swimming direction. (b) SEM images of SHCs. The red arrow 
indicates the horn structure used for enhancing the micromotor motion in blood. Scale bar: 
40 µm. 
 
 Swimming in blood 
Microcaps were mixed with sperm and added into 4× diluted whole blood. We used bovine 
sperm for our experiments as their morphology is similar to human sperm. As a result, we 
observed that free sperm retained a high swimming performance, with an average speed of 
a b 
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76 ± 17 µm/s (n = 17), comparable to free sperm in sperm medium (89 ± 14 µm/s, n = 30). 
However, due to the obstructing blood cells and the lack of guidance, freely swimming sperm 
tended to swim on circular trajectories forming hollow regions from where the sperm were 
not able to escape (see Figure 6.3a,i). When swimming in confined space, such as the oviduct, 
sperm tend to swim near the walls (thigmotaxis), displaying circular or curvilinear 
trajectories due to the chirality of the flagellar beating.157 The asymmetric beating of the 
flagellum pushes the nearby blood cells out of the swimming area. As more and more cells 
are pushed close to each other, the cells form a dense boundary wall, trapping sperm inside 
the formed pool. For that reason, the use of a synthetic component, in particular a magnetic 
cap, serves as a guidance vehicle for sperm to ensure the controllable delivery of therapeutic 
cargoes at the desired location by applying external magnetic fields. As an example, the 
coupling efficiency of sperm and SHC microcaps can reach up to 62 ± 19% (n = 6) with 
respect to the total amount of microcaps. In this case, the sperm concentration was 3×104 
sperm /µL and the number of microcaps was 100 caps/µL.  
In agreement with the hydrodynamic simulations, the magnetic tubular sperm-micromotors 
could not swim in 4× diluted blood for a long period of time due to the heavy load created by 
the stacked blood cells on the flat front side of the tubes, as shown in Figure 6.3a, ii. In 
contrast, SHC sperm-micromotors swam more efficiently, even in 2× diluted blood thanks to 
the front horn which easily squeezed through the blood cell crowd (see Figure 6.3a, (iii). In 
this way, blood cells in front of the micromotor were pushed aside, pass by in the vicinity of 
the cap wall forming a broad wake flow behind the SHC (Figure 6.3b). From 8× to 2× diluted 
blood, the swimming velocity of the SHC sperm-micromotors continuously decreased as 
shown in Figure 6.3c. 
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Figure 6.3. (a) (i) Free sperm moving in 8× diluted blood; Sperm-micromotors with (ii) a 
tubular and (iii) a SHC cap in static 8× blood solution. (b) Image sequence of a SHC sperm-
motor moving in static 2× blood. Transparent blue region indicates the wake flow resulting 
from their motion. (c) Speed comparison of SHC sperm-micromotors varying with the 
dilution of whole blood and sperm medium. n=4. Scale bars: 40 µm. 
 
 Swimming against blood flow 
Some of the barriers that micromotors have to face to operate in the blood stream are the 
high flow rates and the presence of a large number of cells. The physiological blood linear 
velocity in microcirculation (particularly in the venules) is ca. 0.4 mm/s.158 This number 
decreases to ca. 0.15 mm/s at disease sites when suffering for example embolism.159,160 Thus, 
micromotors have to overcome the hitting of blood cells and the resistance from the serum 
flow at a high velocity. To investigate the swimming capability of SHC sperm-micromotors, 
we used PDMS microfluidic chips to mimic blood vessels of ca. 100 µm in diameter and 
a 
b c 
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imposed a continuous or pulsatile flow using a syringe pump for the experiments. Firstly, 
sperm-micromotors were introduced into the microfluidic channel containing 2× diluted 
blood under a flow velocity of 0.167 mm/s to verify their magnetic response and the 
possibility to guide them in such complex conditions (Figure 6.4a). Then, by maintaining the 
permanent magnetic field at a fixed orientation along the microchannel, and keeping the flow 
velocity at 0.167 mm/s, we evaluated the rheotaxis capability of the sperm-cap assembly. 
Positively, we observed a similar behavior of the sperm-micromotors swimming against the 
flow as compared to free swimming sperm, when keeping their orientation upstream using 
an external magnetic field. In the natural case, sperm reorient in fluid flow to align against 
the flow direction and swim upstream through the oviduct channel. This process is still not 
well understood and there are contradictory hypotheses where rheotaxis is explained as a 
purely physical phenomena, or as an active process where the fluid flow is sensed by sperm 
mechanosensitive channels. Recent studies suggest that no significant difference exists in 
both flagellar beating and released Ca2+ ions between rheotaxis and freely swimming sperm, 
indicating that it is mainly a hydrodynamic effect between the sperm flagellum and its 
surrounding fluid flow.161 Based on our experiments, the same concept applies to the sperm-
micromotor, probably because the flagellar beating of the coupled sperm is not affected by 
the cap as it was designed with a large opening and size which fits to the sperm head, 
allowing for full amplitude sperm beating (Figure 6.4b).  
 
 
Figure 6.4. (a) Magnetic guidance of a SHC sperm-micromotor swimming against blood flow 
at a velocity of 0.167 mm/s. Scale bar: 40 µm. (b) Rheotaxis of the sperm-micromotor. Chiral 
beating and imbalance of hydrodynamic force on posterior (Fp) and anterior flagellum (Fa), 
a b 
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if Fp > Fa, a net lift force is generated on the flagellum, perpendicular to the flow direction. 
The lift force provides the sperm-micromotor a rheotactic velocity (Vr) toward the wall, 
leading to a total swimming speed (U) at an angle (θ) to the horizontal direction. 
 
By increasing the fluid velocity, sperm-micromotors also lower their rheotaxis speed until 
reaching a critical blood flow velocity where the speed of the sperm-micromotor decreases 
down to 0 µm/s. If the blood flow velocity exceeds the tolerance limit of the sperm-
micromotor speed, the sperm is not able to swim further and instead is dragged into the 
direction of the blood flow (see Figure 6.5a). Figure 6.5b, i depicts the absolute sperm-
micromotor speed as a function of the blood velocity. When the sperm-micromotor speed 
decreases down to 0 µm/s, the flow velocity is around 0.175 mm/s, indicating that the 
rheotactic speed equals the flow velocity. This value is higher than the swimming speed in 
static blood due to the wall stress shear gradient which facilitates the progression of sperm 
even though the volume flow in the blood vessel is much higher than the natural sperm 
swimming speed. Sperm can also generate stronger thrust force in the presence of a load 
(fluid resistance), as previously reported for flagellated Chlamydomonas cells.162 Additionally, 
sperm-micromotors are expected to swim even against higher flow velocities when using 
channels with larger cross sections. However, in our experiments we used 100 µm channels 
to avoid difficulties visualizing and tracking sperm-micromotors through the dense blood 
cells. To explore the influence of continuously changing flow velocity on the swimming 
performance of sperm-micromotors, we defined a sequence of linearly increasing flow rates 
by using a syringe pump over a time period of 80 s, increasing the flow velocity up to the 
maximum and decreasing it again to the original value. As anticipated, the sperm-
micromotor moves forward at decreasing speeds upon the increase of the flow velocity 
(Figure 6.5b, (ii).  Then, after reaching the threshold flow velocity, the sperm thrust force 
cannot overcome the fluid drag force, and the sperm-micromotor is displaced along with the 
fluid into the direction of the flow. If the flow decreases again, the sperm-micromotor 
recovers its speed but with a slightly lower magnitude, probably due to the sperm energy 
consumption over time and the previously imposed flow load. 
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Figure 6.5. (a) Track of SHC sperm-micromotors against flowing blood at a velocity of (i) 
0.042; (ii) 0.125; (iii) 0.167; (iv) 0.208; (v) 0.292 mm/s. The duration of the tracking in all 
cases was 3 s. Scale bar:  40 µm. (b) Absolute swimming speed of SHC sperm-micromotors 
versus blood flow velocity. (i) Sperm-micromotor speed against varying flow velocity (n = 
4); (ii) Hysteresis loops of speeds of three sperm-micromotors swimming against 
continuously changing blood flow. 
 
Blood circulation in the human body is mainly caused by two powerful driving forces: the 
heart beat for arterial ejection,163 and the muscle pump for venous and capillary returns.164 
The periodicity of the muscle pump depends on the rhythm of the muscular movement. In 
view of this, we programmed the pulsing perfusions to observe the adaptability of the sperm-
micromotor in periodically changing blood flow. We set the impulse cycle as 3 s to mimic the 
a b 
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rhythm of blood return by the respiratory muscle pump under quiet breathing conditions.165 
Figure 6.6a, i shows the forward displacement when the sperm-micromotors swim against 
pulsing blood flow at a velocity of 0.125 mm/s. In 8 cycles of perfusions (24 s), the sperm-
micromotors progressed forward over a distance of about 596 ± 43 µm in total. The 
increasing displacement fluctuated with the pace of the perfusing pulsation. We also 
programmed a stronger pulsing flow at 0.208 mm/s. Although the sperm-micromotor could 
barely progress forward when the perfusion was on, it could still speed up very fast and 
continue moving in between two perfusions (Figure 6.6a, (ii). Moreover, we found a ratchet 
brake mechanism that could help the sperm-micromotor swim against higher pulsing flows. 
In this case, the sperm-micromotors were first guided towards the wall and forced to 
constantly swim near the substrate. Due to the preference of the sperm to move near 
surfaces, also called thigmotaxis, the sperm-micromotor can swim forward parallel to the 
substrate when the flow is off. When the flow is on, the sperm starts swimming against it 
(rheotaxis) until the flow rate reaches the threshold value in which the sperm is not able to 
swim forward (see Figure 6.6b).  After that, the sperm is not able to hold its head upstream, 
thus it is necessary to reorient it by the magnetic field, until the horn in the engineered cap 
is in contact with the channel surface, serving as an anchor.  When the flow decreases again, 
the sperm-micromotor recovers its swimming speed and successfully progresses until the 
next flow peak is reached. As depicted in Figure 6.6b, iii, the flow impact was at that moment 
counterbalanced by the induced static friction between the top horn of the sperm-
micromotor and the substrate. With this mechanism, sperm-micromotors could even resist 
high flow velocities (up to 0.833 mm/s) and still recover to swim forward when the 
perfusion was off.  
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Figure 6.6. (a) SHC sperm-micromotor swimming against pulsing blood flow at (i) 0.125 
mm/s; (ii) 0.208 mm/s. (n = 4). (b) Schematic of the ratchet brake mechanism: (i) Guiding 
the sperm-micromotor toward the substrate; (ii). Sperm-micromotor swimming without 
flow; (iii) Ratchet brake against flow. Fm: magnetic torque. Fp: sperm propulsion. fr: 
hydrodynamic resistance. Fi: blood flow impact. fs: static friction. 
 
 SHC sperm-motor for anti-coagulation application.  
As a primary demonstration of the potential application of the sperm-micromotor for a 
chemical medication in blood, we endowed the sperm-micromotor with an anti-coagulation 
ability. Heparin-loaded liposomes were prepared by extrusion (see details in Section 3.6) 
and covalently immobilized onto SHCs by an EDC/NHS catalytic reaction. In order to 
characterize the loading of heparin within the liposomes, Alexa 488-conjugated heparin was 
used as payload, thus a high fluorescence intensity was detected throughout the liposomes-
functionalized SHCs, indicating an intact immobilization compared to the bare SHCs (Figure 
6.7a). The SEM images in Figure 6.7b illustrate the distribution and density of liposomes on 
a 
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the SHCs. The size of the liposomes varies from 30 to 150 nm. Since a 100 nm pore size filter 
membrane was used to control the liposome sizes, the larger liposomes probably originated 
from liposome fusion during the drying process.84,166 As illustrated in Figure 6.7c, along with 
the increase of the liposome concentration, more and more liposomes are immobilized into 
densely packed arrays on the micromotor surface.  
 
 
Figure 6.7. (a) Fluorescence microscopy images of (i) blank SHC (ii) Alexa 488-Heparin 
loaded liposomes immobilized HSC. Scale bar: 20 µm. (b) SEM of HSC immobilized with 
Heparin-loaded liposomes (50 µM). Scale bars: 3 µm and 300 nm in the magnified image. (c) 
SEM images of SHCs immobilized with different concentrations of liposomes. (i) Bare SHCs. 
(ii) 100 µM. (iii) 200 µM. Scare bars: 200 nm. 
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b 
c 
iii 
ii 
i 
 85 
 
After washing and drying, we re-dispersed the heparin-loaded liposomes, immobilized SHCs 
(HLSs) in PBS and evaluated the anti-coagulation efficiency of the HLS sperm-micromotor 
system by determining the activated clotting time (ACT). Noticing the considerable burst 
release effect (45),167 we only re-dispersed the HLSs in PBS right before used. After activation 
with thrombin, the free-swimming sperm-treated group showed a comparable clotting time 
(95 ± 26 s) to the blank control of 2× diluted whole blood (85 ± 18 s). Bare SHCs (75 ± 26 s) 
did not show a significant influence on the blood clotting, either, presumably because of the 
bio-compatible cap coating. No clotting was found in the HLS sperm-micromotor system 
even after 5 min, demonstrating a high anti-coagulation capability provided by the released 
heparin. Because of medium evaporation, we did not observe the samples for longer times. 
Figure 6.8a illustrates 8× diluted blood samples differently treated with the HLS sperm-
micromotors and the bare SHC sperm-micromotors in microfluidic channels. After 5 min 
activation, blood samples including bare SHC sperm-micromotors had already been found 
with fibrin clots, while the samples treated with HLS sperm-micromotors were still clean 
with well dispersed single blood cells throughout. Furthermore, a whole blood incubation 
assay was implemented to quantitatively analyze the anti-coagulant activity of HLS sperm-
micromotors in human blood. Prothrombin fragment F1+2168 and integrin CD11b,169 as 
markers of the coagulation cascade and granulocyte activation processes, respectively, were 
determined to evaluate the coagulation and inflammation levels of the treated blood. As 
shown in Figure 6.8b and c, the sperm-motors induced the lowest F1+2 concentration, while 
the bare SHCs and sperm samples did not deviate from the blank blood. All groups had 
commensurate counts of CD11b, which showed that both the SHCs and the sperm did not 
induce any obvious innate inflammatory response. The significantly lower level of 
hemostasis activation in the HLS sperm-micromotors group reflected a valuable heparin-
induced anti-coagulation effect. Despite the fact that more detailed studies are still needed 
to push forward this effort to application, for instance studies on the encapsulating efficiency 
and stability of the liposomes, our results open up a potential application of micromotors 
towards the protection of the circulatory system from blood clot formation. In this scenario, 
HLS sperm-micromotors would be propelled and guided near the embolism sites, suppress 
the hemostasis activation by releasing heparin gradually into the environment and 
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consequently prevent further blood clots. In the future, this system could be further 
expanded to load various thrombolytic drugs for the therapy of already formed thrombus. 
 
 
Figure 6.8. (a) Activated clotting of the blood treated with (i) bare SHC sperm-micromotors 
and (ii) HLS sperm-micromotors. Red arrow points at fibrin clot. Scale bar: 100 µm. (b) 
CD11b level indicating coagulation cascade activation. (n = 6). (c) F1+2 level indicating 
granulocyte activation. (n = 6). 
 
 Summary 
a 
b c 
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To summarize, we developed a blood adapted sperm-motor which could efficiently swim 
against blood flow comparable to the real blood stream in human body. This streamline-
horned sperm-motors were able to work not only as individuals, but also as swarms to 
execute missions in flowing blood. The functionalized sperm-motors showed a significant 
anti-coagulant effect while the non-functionalized sperm-motors did not. The immobilized 
liposomes are also open for further functionalizations, for example with thermal-
sensitive17038 shells, or functional groups sensitive to activated coagulation factors168 toward 
triggered release or specific targeting.  
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7. Transport of multiple motile sperm cells 
 Background 
Chapter 4, 5 and 6 have presented tetrapod-like, streamlined and SHC sperm-motors for the 
applications in both oviduct and the blood. However, all of these three were only for single 
sperm transport. In the drug delivery application, the sperm amount directly determines the 
drug dosage and the anticancer efficiency. The need of multiple sperm guidance can be also 
extended to the in vivo fertilization process, as the success rate is highly dependent on the 
amount of sperm that reach the fertilization site. Such an inefficient way of transporting the 
sperm one by one challenges both the surgical operability and the patient tolerance. Hence, 
it is necessary to establish strategies for collective sperm transport for the future 
applications in reality. Meanwhile, sperm, as a type of live cells, are extremely sensitive to 
the environment. Especially the motility and mobility can be largely decreased if the 
surrounding composition changes or the flagellum is damaged physically. The strategies 
therefore should have no toxicity and avoid direct contact with the sperm.  
 Self-assembled train-like sperm-motors swarm 
This section is based on the publication titled: Sperm Micromotors for Cargo Delivery 
through Flowing Blood. Reprinted with permission from [ACS nano, 2020, 14(3), 2982-2993] 
(doi.org/10.1021/acsnano.9b07851). Copyright [2020] American Chemical Society. 
Sperm-motors with specific design can assemble into a train-like structure under the 
asymmetric magnetization by an external magnetic field, facilitating enhanced transport for 
both multiple sperm and multiple functional microstructures. This section presents an 
example of the assembly of SHCs shown in Chapter 6. The asymmetric magnetization relies 
on partial magnetic coating achieved by depositing Fe at a 75° angle (details are given in 
Section 3.1). Figure 7.1a shows a schematic of the SHCs assembling into a sperm-train. 
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When a uniform magnetic field is applied across the sample with randomly dispersed SHCs 
and sperm, the magnetic layer on each SHC acquires a dipole configuration, leading to the 
alignment of SHCs along the direction of the magnetic field. The dipole-dipole based long-
range attraction between two different SHCs results in their self-assembly. Figure 7.1b 
shows the change of the magnetic field distribution from a single SHC to a 4-SHC sperm-train. 
A more stable field distribution is found after the assembling process, mainly caused by the 
horn of the caps as anchor points within the sperm train. The assembled “train” can be 
further prolonged, stretched and organized with more and more SHCs involved under the 
alignment of the magnetic field (see Figure 7.1c), similar to the assembling process of 
previously reported microcubes.171 The assembling of SHCs can be improved even more by 
decreasing the distance between them (by stirring or by increasing the density of caps in the 
solution).  
 
 
Figure 7.1. Magnetic assembly of SHCs. (a) Schematic of the assembling of two SHCs under 
magnetic field. (b) Magnetization simulations of a SHC and a 4-SHC sperm-train, both with 
partial iron coating. The metal coated part is colored in black. (c) A sperm-train swimming 
in sperm medium (SP-TALP). Red arrows point at the sperm heads. Scale bar: 100 µm. 
a 
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Figure 7.2a shows a sperm-train with 9 SHCs and 7 sperm. The SHCs are periodically 
arranged into opposite directions of the sperm-train, which ensures that the beating of the 
sperm flagellum in one SHC is not disturbed by another, also facilitating the sperm coupling 
to the structures. During the guidance, the sperm-train is still capable to assemble with other 
sperm-trains, breeding a new longer sperm-train but with a lower swimming speed. Finally, 
when the sperm-train arrives at the desired position, we can easily trigger the coupled sperm 
to escape by repeatedly flipping the SHCs and dissembling the sperm-train by abruptly 
turning the magnetic field. In this way, the SHCs are precisely transported and accumulated 
at the desired position.  
This adjustable sperm-train with flexible structure can surprisingly adapt to the swimming 
environment in blood. 4× diluted whole blood was used as a model environment to verify its 
swimming performance for further blood application. As shown in Figure 7.2b, various 
sperm-trains with different numbers of SHCs are assembled and swim in static blood fluid. 
The guidance can be performed not only on a single sperm-train, but also on a troop of 
collective sperm-trains and sperm-micromotors. The swimming performance of sperm-
trains in static blood solution is depicted in Figure 7.2c. The average swimming speed 
generally decreases with the increase of the SHCs numbers in sperm-trains. The cap number 
dependent swimming performance shows the same behavior when the sperm-trains swim 
against flow. For example, as tracked in Figure 7.2d, the average swimming speed of a 4-
SHCs sperm-train against a blood flow of 63 µm/s was 32 µm/s, while a single SHC sperm-
micromotor could swim at a high speed of 97 µm/s. This speed decreases is probably 
because sperm are not pushing the cargoes in a synchronized way. The interference between 
the traveling waves generated by the tail beating of the coupled sperm as well as the 
increased load (caps number) also could influence the resulting swimming speed. In order 
to get a better understanding of the interaction between sperm micromotors within a sperm-
train, further modeling and experiments are required. 
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Figure 7.2. (a) A sperm-train swimming in sperm medium (SP-TALP). Blue arrows point at 
the sperm heads. (b) A troop of sperm-trains swimming in 4× diluted blood. (c) Swimming 
speed of sperm-trains vs cap number. (n = 6). (d) Track of a sperm-train and a SHC sperm-
micromotor swimming against flowing blood. Scale bars: 100 µm. 
 
 Helical microcourier combined with a protein-based microflake 
This chapter is based on the publication titled: Magnetic Micromotors for Multiple Motile 
Sperm Cells Capture, Transport, and Enzymatic Release. Reprinted with permission from 
[Angewandte Chemie, 2020, 59, 2-11] (doi.org/10.1002/anie.202005657). Copyright [2020] 
WILEY-VCH.  
This chapter Magnetically driven micromotors are of great interest because of their fuel-free 
actuation and controllable locomotion based on external magnetic field which can efficiently 
a b 
c 
d 
 92 
 
penetrate tissue without inducing adverse effects.172 Compared to those based on 
translational actuation by magnetic field gradient, micromotors based on oscillating or 
rotating magnetic fields only need very low field strength,50,173 making them safer and more 
adaptable in human body. Indeed, helical microstructures were proposed to transduce the 
rotational actuation achieved from the rotating magnetic field into translational motion.51 
Nelson et al. demonstrated that helical micromotors could be propelled by orthogonal 
rotating magnetic field in a wide range of frequencies and furthermore be used for drug 
delivery targeting single cells.52 Helical micromotors could also be used to manipulate micro-
objects by direct contact pushing174 or by locally induced hydrodynamic vortexes , as a more 
gentle way. For example, helical micromotors with a tubular front end were shown to be able 
to create mobile fluidic traps to capture microbeads without contact and deliver them to the 
desired location under a rotating magnetic field, showing a great potential on the transport 
of delicate cargos.175 
One example of the cargos that that need the special care from micromotors is the sperm. 
However, carrying motile cells represent a big challenge, in particular if the purpose is to 
transport and deliver multiple sperm to the area of interest. In the in vivo fertilization 
process, the success rate highly depends on the sperm amount. It has been found that a 
successful fertilization in vivo needs at least tens to hundreds of sperm to reach the oocyte.176 
In this process, interindividual cooperation among the sperm facilitates the locomotion and 
the sperm penetration through the cumulus cells and the zona-pellucid.177 As well, in the 
drug delivery application, the sperm amount directly determines the drug dosage and the 
anticancer efficiency of the treatment. Such an inefficient way of transporting the sperm one 
by one challenges both the surgical operability and the patient tolerance to the treatment. 
Hence, a harmless micromotor that can transport collective motile sperm with no effect on 
their propulsion is needed. While the collection of immotile sperm can be done by simply 
mechanically trapping, a more robust method with a firm binding mechanism must be 
employed to collect motile sperm given the powerful propulsion of the sperm. In the clinical 
practice of in vitro fertilization, solid-state hyaluronic acid (HA) is widely used for sperm 
selection based on a receptor mediated coupling.178 This method is crucial on the selection 
of healthy sperm as only sperm with intact DNA can successfully express this protein. The 
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binding neither influences the sperm activity nor the tail beating and thus the HA bound 
sperm can be safely used on fertilization.179 Inspiringly, the dramatic interaction between 
HA and sperm can be employed in the research of micromotors for sperm transport. In this 
chapter, we present a magnetically driven microcourier (MC) that can efficiently transport 
sperm clusters, including both motile and immotile ones. The collection of motile sperm 
relies on a microflake (MF) made of bovine serum albumin (BSA) and HA (Figure 7.3). Motile 
sperm then are co-incubated with the HA microflakes, inducing their coupling by ligand-
receptor binding between sperm and HA. Once the sperm are trapped within the microflake, 
a magnetic helical micromotor is approached to the microflake, capturing it due to a locally 
induced hydrodynamic vortex. After being precisely guided to the target zone, the sperm can 
be controllably released by hydrolyzing the microflake mediated by the proteases present in 
the surrounding environment. In the scenario of the application in the reproductive system, 
several proteases, for example Oviductin (~10 µg/mL present in the oviduct),180 will serve 
as the enzymatic trigger to catalyze the hydrolysis of the microflake. Here in this study, we 
employ trypsin at concentrations ranging from 50 to 200 µg/mL to demonstrate the 
principle of operation.  
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Figure 7.3. Concept of the transport of a cluster of motile sperm by the MC-MF system 
 
The MC has a helical body and a tubular head. The helical body was designed as a sing-
threaded screw with a length of 100 µm and a diameter of 50 µm. It was constructed layer-
by-layer in a shape of spiral stairs. Each structural line was exposed horizontally to enhance 
the mechanical stability of the structure. The tubular head was designed as the confinement 
for the target cargo with the same diameter of the helical body. Three prototypes (MC1, MC2 
and MC3 as shown in Figure 7.4a) were fabricated by FSTL, with different mechanisms for 
cargo capture. The MCs were coated with 15 nm Fe and 2 nm Ti respectively as magnetic and 
biocompatible layers. When the helical body rotated synchronously with the external 
magnetic field, it converted rotational motion to translational motion. The MCs could be 
furthermore guided by changing the rotating direction of the field. Different MCs had no 
significant difference on the swimming velocity or the guidance performance. Therefore we 
used MC3 as an example to show the swimming performance the MCs under magnetic 
guidance. Figure 7.4b illustrates the overlay motion sequence of a MC under magnetic 
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guidance. A rough rectangular guidance was performed, reflecting a stable swimming 
behavior of the MC and its fine synchronization with the magnetic field.  As shown in Figure 
7.4c, the swimming performance of the MC was highly influenced by the strength and the 
rotating frequency of the applied magnetic field. From 0 to 4 Hz, the MC responded to the 
magnetic field with chaotic vibration. After the rotation reached the actuation frequency, the 
forward velocity of the MC almost linearly increased with the increase of the rotating 
frequency of the magnetic field until the rotating frequency reached a so-called step-out 
frequency. After that, the MC velocity declined rapidly as it was not able to synchronize with 
the input frequency. Higher field strength could elevate the step-out frequency and therefore 
increase the peak value of the forward velocity. Compared to the previously reported helical 
micromotors with smaller sizes, our MC generated higher swimming velocities with lower 
magnetic field strength and lower frequency. This is attributed to the efficient magnetic 
response and the high synchronization of the big MC with thicker Fe coating to the magnetic 
field. 
 
 
Figure 7.4. Swimming performance of MCs. (a) SEM images of 3 microcouriers. Scale bar: 50 
µm. (b) Swimming velocity of MC3 related to the rotating frequency of the magnetic field. 
Scale bar: 200 µm. (c) Motion sequence of MC3 guided in a rectangular track. 
 
The difference of three types of MCs is manifested in the sperm capturing. We first tested 
MC1 with a cup-like head (Figure 7.4a), which was previously reported to transport cargos 
based on direct contact pushing. Disappointingly, the cargo capturing rate of MC1 was very 
a b c 
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low as the fluid flow created by MC1 always pushed the cargo away. As an improvement, 
MC2 was fabricated with a tube on top of its helical body (Figure 7.4a). The cargo coupling 
relies on a microvortex based noncontact transport, as previously demonstrated by Nelson 
et al.175 When MC2 rotated by the magnetic field and swam forward, the rotary motion of the 
propeller could create a vortex in front of the head. Confined by the tubular head, the vortex 
could pump the nearby object in when the MC2 moved forward. Figure 7.5 showed the 
transport of immotile sperm by MC2. When the MC2 swam near to the immotile sperm, the 
vortex in front of the tubular head pulled the nearby sperm in the fluid trap. The sperm were 
confined in the interior of the vortex by the translational suction force and rotated together 
with the MC. The efficient transport of the cluster of immotile sperm represents a promising 
non-invasive strategy toward asthenospermia, with which patients can provide sufficient 
sperm only in reduced motility. On the other hand, for the patients who have motile but 
reduced amount of sperm, i.e. oligospermatism, it is more important to select the healthy 
sperm and transport to the oocyte.68 However, the aggressive self-propulsion of motile 
sperm stays as a barrier for mechanical capturing. While the immotile sperm were efficiently 
trapped by the fluid vortex, the motile sperm could easily swim away at a high speed. To 
solve this problem, a sperm-friendly strategy is needed to harmlessly fix the sperm for 
mechanical capturing and controllably release them after approaching the target.  
 
 97 
 
 
Figure 7.5. Overlaid motion sequence of the transport of a cluster of immotile sperm by MC2. 
Blue line and arrows depict the track of and directions of the MC movement. Green arrows 
point at the cluster of immotile sperm. Scale bar: 100 µm. 
 
Thermal-assembled BSA/HA microflakes were fabricated to select and carry healthy sperm. 
We first fabricated HA/BSA microbeads by using a micro-emulsion method. The BSA scaffold 
was initiated by heating, while the embedded HA microparticles were cross-linked by 
EDC.181 After gentle milling at 4 degree, the microflake was prepared with a high surface area 
for the sperm to bind on. Solid-state HA was using here for its affinity to sperm as they have 
been extensively used on artificial fertilization thanks to its similar structure to the ligand on 
zona. The receptor mediated sperm binding to HA occurs specifically on mature sperm with 
intact genes.179  Inspired by this, we employed HA particles to capture heathy motile sperm, 
when the BSA scaffold served to carry the sperm-bound HA particles and release the sperm 
after hydroxylation. The microflakes were around 80 µm in diameter and 20 µm in thickness. 
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Each HA particle is around 500 nm in diameter. Low-temperature milling enhanced the 
roughness of the microflake surface and exposed HA particles on it, generating a high 
efficiency of sperm capturing on these exposed binding sites. Figure 7.6a illustrates the 
sperm attachment on the microflake. sperm were captured by the microflake by being bound 
on the front part of the sperm head, revealing an acrosome related reaction. The sperm 
capturing efficiency was affected by the microflake size, the sperm concentration and 
incubation time. The microflake at around 80 µm in diameter could averagely capture 50 
sperm in 10 min co-incubation. Despite the fact that the sperm capturing was more difficult 
over time probably due to the repelling of the captured sperm, the sperm attachment could 
still occur after 30 min when a foreign sperm swam by. 
 
To demonstrate the overall potential of the MC-MF based system for multiple sperm 
transport, we fabricated a microfluidic chamber as an in vitro environment. Although MC2 
could successfully capture single immotile sperm, the BSA-HA microflake repeatedly slipped 
out of the back opening of the tube. Thereupon, we constructed a cross on the bottom of the 
tubular head to assist the microflake carrying without affecting the vortex. Figure 7.6b 
illustrated an entire transport process with an operation strategy as follows: First, the 
microcourier was slowly guided toward the sperm-loaded microflake at a low rotating 
frequency. If the microcourier approached to the targeted microflake at a high speed, the 
docking could be easily lost as the trapping force of the vortex declined rapidly outside the 
tube. When the front opening of microcourier was close to the microflake, the rotating 
frequency was increased to 20Hz to generate a powerful vortex to trap the microflake and 
firmly carry it. After the MC-MF reached to targeted position, the cargo discharge was 
accomplished by simply unscrewing the MC by rotating the magnetic field in the opposite 
direction at 20 Hz. 
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Figure 7.6. (a) Sperm capturing by a BSA-HA MF. Red arrows pointed at one sperm before 
and after being captured. Blue arrows point at a sperm being captured. Scale bar: 50 µm. (b) 
Transport of a motile sperm loaded MF by MC3: (i) approaching to the MF; (ii) picking the 
MF up; (iii) releasing the MF; (iv) track of the whole transport. Blue and red lines depict the 
tracks of the movement before and after picking up the MF. Scale bar: 100 µm. 
 
Finally, the captured sperm were released by enzymatically hydrolyzing the BSA matrix. In 
general, protein hydrolysis occurs on the peptide linkages.182 During the preparation of the 
microflake, the aggregated proteins lose solubility due to an exposure of hydrophobic groups 
after heating. Meanwhile, the aggregated proteins become more unstable, especially in the 
presence of protease, as the peptide linkages were also exposed to water.183,184 We first 
tested the sperm release in PBS without protease. No sperm was released in 1 h of 
observation, revealing a stable coupling of sperm on the microflake. Physiologically, 
proteases are universally present in different organs in human body, while most of them 
exist as known in the digestive system.185 Specifically in the female reproductive system, a 
trypsin-like protease termed “Oviductin” is secreted by the oviduct at a concentration of 
a b i 
iii iv 
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around 80 µg/mL for external protein degradation.186 It plays an important role in the 
reproductive process, including preventing the oviduct obstruction.180 Besides, the sperm 
also release proteases, including the most well-known acrosin, which helps the sperm to 
penetrate the cumulus and zona pellucida.187 These proteases facilitates the hydrolysis of 
foreign proteins, which specifically helps the disintegration of the BSA scaffold in terms of 
this research. To demonstrate the enzymatic sperm release from microflake, we designed an 
accelerated experiment by adding trypsin in the system to mimic the function of the 
proteases in the oviduct. Figure 7.7a illustrates the sperm release based on the enzymatic 
disintegration of the microcourier where the trypsin was used at 100 µg/mL. The 
microcourier was disintegrated very slowly at the beginning, revealing a diffusion time of 
the added trypsin and a water repelling effect by the exposed hydrophobic groups. The first 
sperm was released in the fourth minute. After that, the microcourier was rapidly 
disintegrated and thus the captured sperm detached from the microcourier separately or in 
a bundle with their heads attached on the same BSA-HA block. These bundles of sperm could 
be further released after the attached BSA-HA blocks were completely disintegrated. In the 
end, all the captured sperm swam away in 10 min. After being released, the sperm retained 
their mobility and swam away in random motion. As depicted in Figure 7.7b, the release 
rate of sperm declined as trypsin concentration decreased. Considering the lower 
concentration and the lower proteolytic activity of the protease in the oviduct compared the 
trypsin we used in this experiment,188,189 the auto release of sperm in vivo is expected to be 
gentler than this accelerated experiment. The release time can be further regulated by the 
crosslinking degree of the BSA. In general, sperm can live for several days in the oviduct. This 
guarantees the safety and mobility of the released sperm during a wide range of release time.  
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Figure 7.7. (a) Phase contrast images showing sperm release during MF hydrolysis by 
trypsin. (b) Sperm release numbers over time relative to the total captured numbers. 
 
 Multi-pocket sperm-bus 
Another strategy for multiple sperm transport is to use “multi-pocket sperm-bus”. To do so, 
a large conical tube was designed containing nine micropockets, allowing multiple 
mechanically coupled sperm to simultaneously propel the structure forward (Figure 7.8). 
In this experiment, sperm and multi-pocket caps were co-incubated, similarly to the previous 
experiments in chapter 5 using smaller microcaps. After a few seconds, multiple sperm 
entered the individual cavities and pushed the multi-pocket structures forward. The caps 
were coated with iron to allow their magnetic guidance. Future experiments will focus on 
optimizing the design of these structures to further reduce drag forces and improve the 
overall motion efficiency of the sperm-motors. Thus, it is important to consider how the 
separation and lengths of the cavities might affect the tail beating of the sperm, since external 
confinement of the sperm can influence the resulting motion, as reported previously by our 
a 
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group.69 Additionally, sperm induce traveling waves that can be summed up or cancelled out 
depending on the position of the different sperm within the multi-pocket cap. Although the 
sperm release from the sperm-bus remains a problem, the structure itself could serve as a 
platform for future sperm synchronization studies as well as for investigating the influence 
of sperm head rotation on the overall motion performance of the bio-hybrid micromotor.  
 
 
Figure 7.8. Sperm-bus for multiple sperm transport. (a) CAD Design. (b) Sperm capturing in 
the pocket. (c) Track of the movement of the sperm-bus propelled by coupled sperm. 
  
 Summary 
To summarize, we have demonstrated three robotic systems to transport clusters of sperm. 
Firstly, the SHC sperm-train represents a self-assembly strategy for multiple single 
micromotors transport. The sperm-train comprised of multiple single SHC sperm-motors 
can be guided by external magnetic field one by one and even as a swarm. The streamlined 
figure enables them to efficiently swim in the blood flow. The train-like assembling and 
swarming could not only improve the efficiency of cargo transport, but also enable the 
sperm-motors swarm to swim through narrow capillaries, thanks to the deformable body of 
the sperm-train. The microcourier-microflake system represents a strategy of concentrated 
transportation of sensitive cargos. This integrated system is based on an external magnetic 
field as the power source, a helical micromotor as the courier and a microflake made of BSA 
a b c 
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and HA as the sperm container. We demonstrated the magnetic actuation and the remote 
guidance of the microcourier. The microcourier was optimized to transport not only single 
dispersed immotile sperm but also the clusters of motile sperm with the assistance of the 
microflake. While the immotile sperm were released by simply unscrewing the microcourier, 
release of the motile sperm relied on the enzymatic hydrolysis of the BSA scaffold of the 
microflake. The MC-MF integrated system presented here can be envisioned to be a new 
strategy toward non-invasive artificial fertilization in vivo. The multiple-pocket sperm-bus 
provides a cooperative strategy of multiple self-propelled payloads. This system facilitates 
the loading of multiple cargos and transport of them at once. These three strategies for 
multiple sperm transport can not only work individually for different applications, but also 
be combined together for a more specific use in the future. 
  
 104 
 
8. Conclusions and Outlook 
 Achievements 
This dissertation presents a successful establishment of sperm-based micro-robotic systems 
on the application of drug delivery. sperm, for the first time, are shown to serve as excellent 
candidates to carry anti-cancer drugs (DOX-HCl), attributable to their compact membrane 
system that acts as a protective layer surrounding the drug. One single bovine sperm can 
encapsulate 15 pg of DOX-HCl, while a human sperm can encapsulate 5 pg. The DOX-HCl 
transfer from the incubation solution into the sperm is driven by the binding of the drug on 
the sperm DNA. Almost all sperm including immotile ones can load DOX-HCl in the nucleus. 
DOX-HCl has no negative influence on bovine and human sperm, neither on the viability nor 
on the motility, as the sperm do not perform substance metabolism. In addition, sperm can 
swim through complex environments in an efficient manner not only due to their tail beating 
but also due to their membrane biochemistry. They remain functional in the human body for 
a longer time in comparison to other foreign cells (e.g. bacteria, fungi) due to their ability to 
inhibit the immune response by displaying specific proteins155 and prostasomes156 on the 
membrane. This reduces undesired immune response and thus makes this system more 
compatible to the host body.  
In terms of the application for cancer treatment, the ability of sperm to fuse with somatic 
cells also confers them a unique property to deliver the drug locally into cancer cells through 
sperm-cell membrane fusion. Coupled with different types of magnetic microstructures, 
drug loaded sperm can be engineered to be micro-robotic systems that can be magnetically 
guided to the interest position, like cancer lesions, and release the sperm in a controlled way 
by means of specific trigger. Indeed, the tetrapod-like microstructure with 4 bendable arms 
works as a mechanical trigger for the sperm to escape when the arms reach the target, while 
the streamlined cap can discharge the sperm by abruptly flipping the cap with an external 
magnetic field. Compared to purely synthetic micromotors or other carriers, the here 
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proposed sperm-hybrid micromotor can encapsulate high concentrations of drug inside the 
sperm membrane and hence protect it from the dilution in the body fluids and enzyme 
degradation.  In the foreseeable future, sperm can be also functionalized with imaging 
reporters such as infrared emitting molecules, radioactive isotopes or absorbing 
nanomaterials to improve image contrast in techniques such as optical imaging, positron 
emission tomography or optoacoustic tracking.190 It will be intriguing to test how these 
micromotors perform in vivo in preclinical experiments, a key prerequisite for translating 
this technology to the clinic for future patient benefit. Such a system comprising guidable 
micro-enhancement and drug-loaded sperm can be envisioned to be employed in the future 
targeted cancer treatments in the female reproductive tract. 
Environmental condition and material composition vary among different body fluids in 
human body. It is thus necessary for micromotors to adapt in different working 
environments. Propelled by sperm, a body-derived powerful propeller, sperm-hybrid 
micromotors can work not only in the reproductive system, but also in the blood. The sperm 
does not induce clotting or inflammation in the blood, while the blood composition has no 
deleterious effect on the sperm motility either. Equipped with a horn-like part, the 
streamlined sperm-motor can squeeze in the blood cells crowd so as to efficiently swim in 
blood with highly dense blood cells. The powerful propulsion provided by the sperm 
flagellum enables the sperm-motor to resist the blood at a high flow velocity comparable to 
the blood velocity in the microcirculation in human body. Gifted by nature, the sperm owns 
the rheotaxis ability to swim towards the wall and against the flow, enabling the sperm-
motor to overcome stronger blood flow. By using specific guidance strategy, a ratchet-
mechanism can help the sperm-motor swim against pulsing blood flow faster than 800 µm/s. 
The coupled microstructure can be furthermore functionalized with anticoagulant drug. The 
drug loaded sperm-motor can then serve as an anticoagulant micro-surgeon which can 
inhibit the growing of the blood clots at desired locations after precise guidance. 
Medical practice do not have much tolerance on inefficient transport of single micromotors 
one by one. From single to swarm, collective transport of sperm-motors stands as an 
important milestone on the way to the clinical application, showing value on increasing the 
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drug dose in this particular application. The self-assembled sperm-trains are employed to 
transport both multiple sperm and multiple cargo-loaded artificial parts. The tapered horn 
on the streamlined cap here acts as an anchor to connect to another cap by dipole-dipole 
attraction under magnetization. The assembled sperm-train is then propelled by the coupled 
multiple sperm and guided by the external magnetic field to the target. The slender shape 
enables it to go through narrow channels. Artificial caps and sperm can be finally released 
after the sperm-train is dissembled by abruptly flipping the magnetic field, realizing the 
targeted cargo delivery.  This strategy can efficiently work as individuals and in swarm to 
transport multiple sperm in not only artificial cell medium but also ex vivo flowing blood. 
To transport more sperm at once, a combined system of a magnetic microcourier and a 
protein-based microflake are utilized. Up to 50 motile sperm can be captured on the 
microflake at once without damage. The sperm captured microflake can be then transported 
by the helical microcourier under magnetic propulsion. When the microflake is 
enzymatically degraded by the body fluid, sperm can be released at the desired position to 
do the job of fertilization or cancer treatment if they are loaded with drug. This system can 
not only be used to efficiently transport sperm in a cluster, but also inspiring a new way to 
transport other biological organisms that needs special care. The strategy can be concluded 
as: encapsulate the sensitive organisms in a container, transport the loaded container by a 
micromotor and release the organisms out of the container at the presence of specific 
enzymes. Some other strategies for multiple sperm transport are also explored. For example, 
single sperm-motors with the same asymmetric shape of magnetic coatings can be aligned 
and guided to the same direction in the magnetic field. The fabrication is simple but the 
operation is not because sperm-motors starting from different positions cannot reach to the 
target at the same time. A multi-pockets sperm-bus shows up as another option. The sperm-
bus loads multiple sperm in its pockets and is guided under the propulsion of these sperm 
to fulfill the goal of transport multiple sperm at once. Nonetheless, the coupling between the 
sperm and the sperm-bus has to be so firm to guarantee a stable propulsion that the sperm 
release comes out as an issue.  
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Finally, by realizing the navigation of the sperm-based micro-robotic system from single to 
multiple, this dissertation opens up the gate of sperm-based drug delivery and inspires its 
application in varieties of realistic body environments. 
 Outlook 
Sperm-motors as a targeted delivery system represents a range of possibilities. For example, 
this non-invasive treatment could lead to the next generation of robotic medical procedure, 
especially towards the diseases in the female reproductive tract. In this scenario, sperm are 
loaded with essential medicines in advance and coupled with the guidable microstructures 
with certain release mechanisms. The administration route will be via the vagina and deep 
into the uterus at a location nearby the oviduct. The whole process does not induce any 
damage to the human body or exchange any substances with the circulation system of the 
human body. A 3D magnetic field will be used then to guide the cluster of these micro-
surgeons to the target. The precision can be extended to the scale on a single pathogen or 
injured cell. In addition, the sperm-motors can be also introduced through the blood as they 
can efficiently swim against the blood flow. Blood diseases or the disease sites with ruptured 
vessels (e.g. hepatitis) will be the target in this case. Such devices can be also engineered to 
carry genes, mRNA, imaging contrast agents or other substances of interest for diverse 
biomedical applications. On the exciting way of micromotors to the clinic, some milestones 
can be prospected.  
8.2.1. Biology study 
(1) It is necessary to investigate the drug loading mechanism before a mass of drugs are 
examined on sperm. The experiment can be done relying on mature molecular biological 
tools. Ion channels and translocators can be screened for a better understanding of the 
involving of the sperm membrane on the transmembrane transport of DOX-HCl or any other 
drugs during loading. Specific gene knockout can be used to load a specific drug by excluding 
the other out or provide a wide loading spectrum for multiple drugs as a cocktail therapy. 
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(2) The drug uptake mechanism by the targeted cell stays as another biochemical attraction. 
We confirmed the function of cell-fusion of the sperm on the DOX-HCl transfer, but the 
molecular participation behind this cell-fusion is still unknown.  
8.2.2. Robotics study 
(1) Since micromotors were developed not earlier than 20 years ago, there has been no 
perfect one that can be applied in clinic so far. With respect to sperm, a cooperative 
microscale enhancement is needed. These enhancements should have a stable structure that 
can firmly couple the sperm, possess a sensitive response to the external guidance and a 
smart trigger to be controlled, be made of biocompatible and degradable material for the 
concern of the application safety. 3D lithography turns out to be an advantageous means to 
fabricate such structures. The next steps would be to include more editable materials, such 
as polyisopropylacrylamide as thermal sensitive trigger, polypyrrole as elastic joint, 
polyethylene dioxythiophene as conductive part to construct one micromotor with a 
compound system. 
(2) The real-time tracking under deep tissue needs to be improved as the current imaging 
techniques (e.g. ultrasound and magnetic resonance imaging) are too coarse.34 The recently 
developed photoacoustic imaging could be an answer for this. The micromotors could be 
polished with photosensitive surface, or modified with photo sensitive nanoparticles or 
quantum dots so that intense ultrasonic signal can be detected after efficient laser 
excitation.190  
As a fascinating interdisciplinary study including biology, polymer science, photonics and 
robotics, to construct a sperm cyborg is never easy concerning the operation precision at the 
microscale and the coadaptation of the sensitive biological cell and the artificial 
enhancement. Nevertheless, as the abovementioned challenges are being answered step by 
step, patients in clinic will delightedly benefit from the sperm-motors. In this road, we hope 
that this dissertation can contribute to fulfill the great goal raised by Feynman: to apply the 
microscale surgeon in the human body. 
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